Note: Descriptions are shown in the official language in which they were submitted.
CA 02548918 2006-06-09
' 27103-500
DESCRIPTION
a-AMINO ACID DERIVATIVES AND USE THEREOF AS MEDICINES
Technical Field
[0001]
The present invention relates to an a-amino acid
derivative having a DPP-IV inhibitory action, use thereof as
medicines and production method thereof.
Background Art
[0002]
/o DPP-IV is a serine protease, which recognizes an amino
acid sequence having proline (or alanine or hydroxyproline)at
the penultimate position from the N-terminal and produces
dipeptide Xaa-Pro (Xaa shows an optional amino acid and Pro
shows L-proline). DPP-IV is widely distributed in mammalian
tissues and is known to be present particularly in blood,
kidney, intestinal epithelium and placenta.
[0003]
While the physiological role of DPP-IV in mammal has not
been completely elucidated, its involvement in a broad range
of functions of living organisms such as degradation of
neuropeptide (see non-patent reference 1), activation of T
cell (see non-patent reference 2), adhesion of metastatic
tumor cell to endothelium (see non-patent reference 3),
invasion of HIV virus into lymphocytes (see non-patent
reference 4) and the like is being clarified. Of these, the
role of DPP-IV as an enzyme that inactivates glucagon-like
peptide (GLP-1), which is a biogenic substance having a strong
insulin secretion ability and controls postprandial blood
glucose level, has been drawing attention (see non-patent
reference 5).
[0004]
GLP-1 is known to be metabolized in several minutes in a
living organism. In the metabolism, that by DPP-IV is
particularly important, because DPP-IV quickly cleaves GLP-1
to produce inert GLP-1 (see non-patent reference 6). In
1
CA 02548918 2006-06-09
addition, it is considered that physiological action of GLP-1
becomes attenuated further because this inert GLP-1 shows an
antagonistic action on GLP-1 receptor (see non-patent
reference 7). Therefore, a method for suppressing cleavage of
GLP-1 by inhibition of DPP-IV is considered to be the most
superior approach for reinforcing GLP-1 action. That is, a
DPP-IV inhibitor is expected to be a superior treatment method
of curing postprandial hyperglycemia without side effects,
such as prolonged hypoglycemia and the like, for non insulin-
" dependent diabetic (type II diabetes) patients.
[0005]
Patent applications directed to DPP-IV inhibitors have
been already filed.
A compound consisting of a natural amino acid and
thiazolidine or pyrrolidine is known to show a DPP-IV
inhibitory action (see patent reference 1). Besides this
reference, compounds consisting of cyclohexylglycines and
thiazolidine have been disclosed (see patent reference 2).
patent reference 1: W099/61431
patent reference 2: W002/76450
non-patent reference 1: Heymann et al., FEBS Letters, vol. 91,
360-364 (1978).
non-patent reference 2: Schon et al., Biomedica Biochimica
Acta., vol. 44, K9-K15 (1985).
non-patent reference 3: Johnson et al., Journal of Cell
Biology, vol. 121, 1423-1432 (1993).
non-patent reference 4: Callebaut et al., Science, vol. 262,
2045-2050 (1993).
non-patent reference 5: Deacon et al., Journal of Clinical
Endocrinology and Metabolism, vol. 80, 952-957 (1995).
non-patent reference 6: Deacon et al., American Journal of
Physiology, vol. 271, E458-E464 (1996).
non-patent reference 7: Knudsen et al., European Journal of
Pharmacology, vol. 318, 429-435 (1996).
Disclosure of the Invention
2
CA 02548918 2006-06-09
Problems to be Solved by the Invention
[0006]
There are many reports on DPP-IV inhibitors to the
present [Wiedeman et al., Current Opinion in Investigational
Drugs, vol. 4, 412-420 (2003) etc.]. While they influenced the
progress of drug discovery techniques, a compound providing
sufficient clinical effects has not been reported, and the
development of a more effective inhibitor has been desired.
Means of Solving the Problems
[0007]
In view of the above-mentioned points, the present
inventors have conducted intensive studies with the aim of
developing a novel DPP-IV inhibitor. As a result, the present
inventors have found that a-amino acid derivatives have potent
DPP-IV inhibitory activities, and made the stability higher,
which resulted in the completion of the present invention.
[0008]
Accordingly, the subject matter of the present invention
rests in the following (1) to (12).
(1) An a-amino acid derivative of the formula (I)
[0009]
,x,,
R
Z132
( I )
H2NThrN
0
[0010]
wherein
Rl is a hydrogen atom, a halogen atom, alkyl or alkoxy,
R2 is a hydrogen atom, a halogen atom, a hydroxyl group,
alkyl or alkoxy, or
Rl and R2 are joined to form oxo, hydroxyimino, alkoxyimino or
alkylidene,
x is CH-R2 or N-R4,
is CR5R6
wherein R5 and R6 are each a hydrogen atom, a
halogen atom, a hydroxyl group, alkyl or alkoxy, or
3
CA 02548918 2006-06-09
R5 and R6 are optionally joined to form oxo,
hydroxyimino, alkoxyimino or alkylidene,
S, S=0 or SO2,
is a hydrogen atom or cyano,
m and n are each 0, 1 or 2, wherein the sum of m and n is 1, 2
or 3,
is 0, 1, 2 or 3,
R3 is -NR7R8
wherein R7 and R9 are optionally the same or
different and each independently is a hydrogen atom,
alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl,
heteroaryl or heteroarylalkyl, or are optionally
bonded to each other to form heterocycle having at
least one nitrogen atom, and optionally having other
further hetero atom(s),
wherein the heterocycle is optionally
substituted or condensed with an aromatic ring
optionally having substituent(s),
-NR9COR3-9
wherein R9 and RI are optionally the same or
different and each independently is a hydrogen atom,
alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl,
arylalkenyl, heteroaryl, heteroarylalkyl or
heterocycle,
-NR11CONR12R13
wherein Ril, R" and R" are optionally the same or
different and each independently is a hydrogen atom,
alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl,
heteroaryl or heteroarylalkyl, or R" and R" are
optionally bonded to each other to form heterocycle
having at least one nitrogen atom, and optionally
having other further hetero atom(s),
wherein the heterocycle is optionally
substituted or condensed with an aromatic ring
optionally having substituent(s),
4
CA 02548918 2006-06-09
-NR14S02R15
wherein R14 and R15 are optionally the same or
different and each independently is a hydrogen atom,
alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl,
heteroaryl, heteroarylalkyl or heterocycle,
-0R16 or -000R17
wherein R16 and R1.7 are each a hydrogen atom, alkyl,
cycloalkyl, cycloalkylalkyl, aryl, arylalkyl,
heteroaryl, heteroarylalkyl or heterocycle, and
lo R4 is a hydrogen atom, alkyl, cycloalkyl, cycloalkylalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl,
heterocycle, -CORI
wherein RIE1 is a hydrogen atom, alkyl, cycloalkyl,
cycloalkylalkyl, aryl, arylalkyl, arylalkenyl,
heteroaryl, heteroarylalkyl or heterocycle,
-CONR1 R20
wherein 1219 and R2 are optionally the same or
different and each independently is a hydrogen atom,
alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl,
heteroaryl or heteroarylalkyl, or R19 and R2 are
optionally bonded to each other to form heterocycle
having at least one nitrogen atom, and optionally
having other further hetero atom(s),
wherein the heterocycle is optionally
substituted or condensed with an aromatic ring
optionally having substituent(s), or
-SO2R21
wherein R21 is alkyl, cycloalkyl, cycloalkylalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl or
heterocycle,
provided that when p is 0, then X is CH-R3, and R3 shows the
formula (II)
[0011]
7-7\
--N (H)
5
CA 02548918 2006-06-09
[0012]
wherein
[0013]
is a single bond or a double bond,
[0014]
Rn is aryl or heteroaryl,
is 1 or 2, and
A is a carbon atom or a nitrogen atom,
provided that i) when A is a carbon atom, then A is
optionally substituted by a hydroxyl group, carboxyl
or alkoxycarbonyl, and ii) when A is a nitrogen
atom, then
[0015]
--- is a single bond,
[0016]
wherein, of the above-mentioned groups, alkyl, cycloalkyl,
cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl
and heterocycle optionally have substituent(s),
or a pharmaceutically acceptable salt thereof.
(2) The a-amino acid derivative of the aforementioned (1),
wherein, in the formula (I) of the aforementioned (1), m = 2,
n = 0 and X = CH-R3, or a pharmaceutically acceptable salt
thereof.
(3) The a-amino acid derivative of the aforementioned (2),
wherein, in the formula (I) of the aforementioned (1), R3 is
the formula (II) of the aforementioned (1), or a
pharmaceutically acceptable salt thereof.
(4) The a-amino acid derivative of the aforementioned (3),
wherein, in the formula (I) of the aforementioned (1), Y = S
and Rl= R2= Z = H, and in the formula (II) of the
aforementioned (1), q = 1 and A = N, or a pharmaceutically
acceptable salt thereof.
(5) A compound of the formula (III)
[0017]
6
CA 02548918 2006-06-09
l-Jrn 1
zY R
2
111 )
R
0
[0018]
wherein
X' is CH-R3, N-R4 or C=0,
R23 is -00R24
wherein R24 is a hydrogen atom, alkyl, cycloalkyl,
cycloalkylalkyl, aryl, arylalkyl, heteroaryl,
heteroarylalkyl or heterocycle, or
-COOR25
wherein R25 is alkyl, cycloalkyl, cycloalkylalkyl,
aryl, arylalkyl, heteroaryl, heteroarylalkyl or
heterocycle, and
other symbols are as defined in the aforementioned (1).
(6) The compound of the aforementioned (5), wherein, in the
formula (III), X'= C=0.
[0019]
The present invention also relates to the following
pharmaceutical composition, inhibitor, and therapeutic agent.
(7) A pharmaceutical composition comprising an a-amino acid
derivative of any of the aforementioned (1) to (4) or a
pharmaceutically acceptable salt thereof and a
pharmacologically acceptable carrier.
(8) A DPP-IV inhibitor comprising an a-amino acid derivative
of any of the aforementioned (1) to (4) or a pharmaceutically
acceptable salt thereof.
(9) An agent for the prophylaxis and/or treatment of a disease
relating to a DPP-IV inhibitor, which comprises an a-amino
acid derivative of any of the aforementioned (1) to (4) or a
pharmaceutically acceptable salt thereof as an active
ingredient.
(10) An agent for the prophylaxis and/or treatment of diabetes
or obesity, which comprises an a-amino acid derivative of any
of the aforementioned (1) to (4) or a pharmaceutically
7
CA 02548918 2012-03-22
27103-500
acceptable salt thereof as an active ingredient.
[0020]
[0020a] Specific aspects of the invention are
an a-amino acid derivative of the formula (I)
X
m
Y R1
n (I)
H2N
0
wherein
R1 is a hydrogen atom,
R2 is a hydrogen atom,
X is CH-R3,
Y is S,
Z is a hydrogen atom,
m = 2,
n = 0,
p is 0, or 1,
R3 is -NHR7
wherein R7 is phenyl, phenyl-C1_3a1ky1 which may be substituted by nitro, or
the
formula (II)
8
CA 02548918 2012-10-23
=
27103-500
/
22
A_R
-N ( )
\ __________
wherein
_______ is a single bond or a double bond,
R22 is: a pyridyl which may be substituted by one or two
substituent(s) selected from the group consisting of cyano,
halogen, Ci_olkyl, and trifluoromethyl; a thiazolyl which may
be substituted by cyanophenyl; a pyrazolyl which may be
substituted by one or two substituent(s) selected from the
group consisting of phenyl and Cl_olkyl; an isoquinolyl which
may be substituted by one or two substituent(s) selected from
the group consisting of halogen and trifluoromethyl;
benzothiazolyl; benzoimidazolyl; or phenyl,
q is 1 or 2, and
A is a carbon atom or a nitrogen atom,
provided that i) when A is a carbon atom, then A may be
substituted by a hydroxyl group, carboxyl or alkoxycarbonyl,
and ii) when A is a nitrogen atom, then
--- is a single bond,
provided that when R3 is -NHR7, then p is 1,
or a pharmaceutically acceptable salt thereof;
a compound of the formula (III)
8a
CA 02548918 2012-03-22
27103-500
m
Y Ri
)p
( III )
R 23 N
O
wherein
X' is CH-R3,
R23 is -000R25
wherein R25 is C1_6a1ky1, C3_6cycloalkyl, C3_6cycloalkylalkyl, phenyl, or
phenyl-C1_6a1ky1,
and R1, R2, R3, Y, Z, N, m, n and p are as described herein;
a pharmaceutical composition comprising an a-amino acid derivative as
described herein or a pharmaceutically acceptable salt thereof and a
pharmacologically acceptable carrier;
a DPP-IV inhibitor comprising an a-amino acid derivative as described herein
or
a pharmaceutically acceptable salt thereof;
the a-amino acid derivative as described herein or a pharmaceutically
acceptable
salt thereof, for use in the prophylaxis and/or treatment of a disease
relating to a
DPP-IV inhibitor;
the a-amino acid derivative as described herein or a pharmaceutically
acceptable
salt thereof, for use in the prophylaxis and/or treatment of diabetes or
obesity;
the pharmaceutical composition as described herein, for use in the
prophylaxis and/or treatment of a disease relating to a DPP-IV inhibitor;
8b
CA 02548918 2012-03-22
27103-500
the pharmaceutical composition as described herein, for use in the
prophylaxis and/or treatment of diabetes or obesity;
use of the a-amino acid derivative as described herein, or a pharmaceutically
acceptable salt thereof, for the prophylaxis and/or treatment of a disease
relating to a
DPP-IV inhibitor;
use of the a-amino acid derivative as described herein, or a pharmaceutically
acceptable salt thereof, for the prophylaxis and/or treatment of diabetes or
obesity;
and
use of the a-amino acid derivative as described herein, or a pharmaceutically
acceptable salt thereof, in the manufacture of a medicament for the
prophylaxis and/or treatment of a disease relating to a DPP-IV inhibitor,
diabetes or obesity.
(11) The method of producing a compound of the aforementioned (5)
wherein X' is represented by CH-R3, which comprises use of a compound of the
aforementioned (6) as an intermediate.
(12) The method of producing a compound of any of the
aforementioned (1) to (4), which comprises the production method of the
aforementioned (11).
Effect of the Invention
[0021]
The compound of the present invention shows a potent
DPP-IV inhibitory activity and is useful for the prophylaxis and/or treatment
of
diabetes or the prophylaxis and/or treatment of obesity.
8c
CA 02548918 2012-03-22
27103-500
Best Mode for Embodying the Invention
[0022]
The present invention is explained in detail in the following.
[0023]
Alkyl is, for example, linear or branched chain alkyl having
1 to 10 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl,
isobutyl,
sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl,
nonyl,
decyl and the like, with preference given to lower alkyl having 1 to 6 carbon
atoms
and the like.
[0024]
Cycloalkyl is, for example, cycloalkyl having 3 to 7 carbon atoms such
as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
The
cycloalkyl may be condensed with a benzene ring to form indane (e.g., indan-1-
yl,
indan-2-yletc.)1 tetrahydronaphthalene (e.g., tetrahydronaphthalen-5-yl,
tetrahydronaphthalen-6-yletc.) and the like (preferably indane etc.), and the
cycloalkyl may be crosslinked via a linear atom chain having 1 or 2 carbon
atoms to
form a crosslinked cyclic hydrocarbon
8d
CA 02548918 2006-06-09
residue such as bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl,
bicyclo[3.2.2]nonyl and the like (preferably, cyclohexyl
having crosslink via a linear atom chain having 1 or 2 carbon
atoms etc., more preferably, bicyclo[2.2.1]heptyl etc.).
[0025]
Cycloalkylalkyl comprises a cycloalkyl moiety as defined
above, and an alkyl moiety, which is preferably a linear or
branched chain having 1 to 3 carbon atoms, and is exemplified
by cyclopropylmethyl, 2-cyclobutylethyl, 3-cyclopentylpropyl,
cyclohexylmethyl, 2-cyclohexylethyl, cycloheptylmethyl and the
like.
[0026]
Aryl is preferably aryl having 6 to 14 carbon atoms and,
for example, phenyl, naphthyl, an ortho fused bicyclic group
having 8 to 10 ring atoms, wherein at least one ring is an
aromatic ring (e.g., indenyl etc.) and the like can be
mentioned.
[0027]
Arylalkyl comprises an aryl moiety as mentioned above and
an alkyl moiety which may be preferably a linear or branched
chain having 1 to 3 carbon atoms and, for example, benzyl,
benzhydryl, phenethyl, 3-phenylpropyl, 1-naphthylmethyl, 2-(1-
naphthyl)ethyl, 2-(2-naphthyl)ethyl, 3-(2-naphthyl)propyl and
the like can be mentioned.
[0028]
Heteroaryl is preferably a 5- or 6-membered ring group
having carbon and 1 to 4 hetero atoms (oxygen, sulfur or
nitrogen), or ortho fused bicyclic heteroaryl having 8 to 10
ring atoms induced therefrom, particularly, a benz derivative,
a derivative obtained by fusing with a propenylene,
trimethylene or tetramethylene group, stable N-oxide thereof
and the like. For example, pyrrolyl, furyl, thienyl, oxazolyl,
isoxazolyl, imidazolyl, thiazolyl, isothiazolyl, pyrazolyl,
triazolyl, tetrazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadiazolyl,
1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, pyridy1(2-pyridyl, 3-
9
CA 02548918 2006-06-09
pyridyl, 4-pyridy1), pyrazinyl, pyrimidinyl, pyridazinyl,
1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl,
benzoxazolyl, benzisoxazolyl, benzothiazolyl,
benzisothiazolyl, benzimidazolyl, oxazolopyridyl,
imidazopyridazinyl, thianaphthenyl, isothianaphthenyl,
benzofuranyl, isobenzofuranyl, benzothienyl, chromenyl,
isoindolyl, indolyl, indolinyl, indazolyl, isoquinolyl,
quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl,
cinnolinyl, 2,1,3-benzoxadiazolyl, benzoxazinyl and the like
/o can be mentioned.
[0029]
Heteroarylalkyl comprises a heteroaryl moiety as defined
above and the like, and an alkyl moiety which may be
preferably a linear or branched chain having 1 to 3 carbon
atoms, and, for example, 2-pyrrolylmethyl, 2-pyridylmethyl, 3-
pyridylmethyl, 4-pyridylmethyl, 2-thienylmethyl, 2-(2-
pyridyl)ethyl, 2-(3-pyridyl)ethyl, 2-(4-pyridyl)ethyl, 3-(2-
pyrrolyl)propyl, 4-imidazolylmethyl and the like can be
mentioned.
[0030]
Heterocycle is saturated or unsaturated and has at least
one nitrogen atom, and optionally has other further hetero
atom(s) (oxygen or sulfur). It includes not only monocycles
but also a spiro ring, with preference given to a 10- or 11-
membered ring group, which is a spiro ring, or a 4- or 7-
membered monocyclic ring group. As the heterocycle, for
example, azetidinyl, pyrrolidinyl, piperidino, piperazinyl,
morpholino, 1,4-diazepanyl, 1,2,5,6-tetrahydropyridyl,
thiomorpholino, oxothiomorpholino, dioxothiomorpholino, 3-
azaspiro[5.5]undecyl, 1,3,8-triazaspiro[4.5]decyl and the like
can be mentioned.
[0031]
The above-mentioned heterocycle may be substituted or
condensed with an aromatic ring optionally having
substituent(s). As the aromatic ring of the aromatic ring
CA 02548918 2006-06-09
27103-500
optionally having substituent(s), for example, benzene ring,
pyridine ring and the like can be mentioned. As the fused
ring, for example, indolinyl, isoindolinyl, 1,2,3,4-
tetrahydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl,
phthalimido, indolyl, benz-3-azepine and the like can be
mentioned.
[0032]
Alkoxy is, for example, linear or branched chain alkoxy
having 1 to 10 carbon atoms, such as methoxy, ethoxy, propoxy,
isopropoxy, butoxy, pentyloxy, hexyloxy, octyloxy and the
like, with preference given to lower alkoxy having 1 to 6
carbon atoms and the like.
[0033]
As halogen, chlorine, bromine, fluorine and iodine can be
mentioned.
[0034]
As haloalkyl, trifluoromethyl, 2,2,2-trifluoroethyl,
pentafluoroethyl and the like can be mentioned.
[0035]
Of the above-mentioned substituent(s), alkyl, cycloalkyl,
cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl
and heterocycle are each optionally substituted by one or more
substituents shown below.
[0036]
As these substituents, for example, halogen, hydroxyl
group, nitro, cyano, trifluoromethyl, alkyl, alkoxy,
alkylthio, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl,
heteroaryl, heteroarylalkyl, heterocycle, formyl, acyloxy,
oxo, COORa, CH2COORa, -OCH2COORa, -CONRbRc, -CH2CQNRbRc (Q is =0
or =S) , -OCH2CONPbEtc, -COO(CH2)2NP.01, S02 T1, - CONRdSO2T1, NReRf,
-NRgCHO -NRgC OT2 -NRgCOOT2 -NRgCONRiRj -NR002T3 SO2NR1Rm,
-SO2NRnOCT4, methylenedioxy, ethyleneoxy and the like can be
mentioned.
[0037]
These substituents may further have substituent(s) and,
11
CA 02548918 2006-06-09
for example, as aryl having substituent(s), heteroaryl having
substituent(s) and heterocycle having substituent(s), 4-
cyanophenyl, 4-chlorophenyl, 4-methoxyphenyl, 4-hydroxyphenyl,
4-fluorophenyl, 2,4-dichlorophenyl, 2-chloro-4-methoxyphenyl,
2,4-difluorophenyl, 5-cyano-2-pyridyl, 5-chloro-2-pyridyl, 1-
ethoxycarbony1-4-piperidinyl and the like can be mentioned.
[0038]
Here, as the substituent(s) of the above-mentioned
substituents, halogen, alkyl, alkoxy, cycloalkyl,
cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl
and heterocycle are as defined above.
[0039]
Alkylthio is, for example, linear or branched chain
alkylthio having 1 to 10 carbon atoms such as methylthio,
ethylthio, propylthio, butylthio, pentylthio, hexylthio,
octylthio and the like, with preference given to lower
alkylthio having 1 to 6 carbon atoms and the like.
[0040]
Acyloxy is, for example, linear or branched chain acyloxy
having 1 to 10 carbon atoms such as formyloxy, acetyloxy,
propionyloxy, butyryloxy, valeryloxy, pivaloyloxy,
hexanoyloxy, benzoyloxy and the like, with preference given to
lower acyloxy having 1 to 6 carbon atoms and the like.
[0041]
Ra to Rn are each hydrogen, alkyl (as defined above) or
arylalkyl (as defined above).
[0042]
Rb and Rn, R. and Rf, Ri and Rj, and Ri and R. of -NRbRc,
-NR,12f, -NRiRj and -NR112, are each optionally bonded to each
other to form heterocycle having at least one nitrogen atom,
and optionally having other further hetero atom(s), wherein
the heterocycle is optionally substituted or condensed with an
aromatic ring optionally having substituent(s) (as defined
above, optionally substituted by the aforementioned
substituent(s)).
12
CA 02548918 2006-06-09
Moreover, -NReRf may show heteroaryl having =0 (e.g., 2-
pyrrolidinon-1-yl, succinimido, oxazolidin-2-on-3-yl, 2-
benzoxazolinon-3-yl, phthalimido, cis-hexahydrophthalimido
etc.).
[0043]
Tl to T4 are each a hydrogen atom, alkyl, cycloalkyl,
cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl
or haloalkyl, which is optionally substituted by the
aforementioned substituent(s). Q is =0 or =S.
[0044]
The disease relating to a DPP-IV inhibitor is a disease
for which a DPP-IV inhibitor is expected to show a prophylaxis
and/or treatment effect, such as a disease developed by a DPP-
IV action, a disease whose symptom is aggravated by a DPP-IV
action, a disease whose cure is delayed by a DPP-IV action and
the like. Specific preferable examples include diabetes,
obesity and the like.
[0045]
The compound (I) can show polymorphism, and can be
present as two or more tautomers.
[0046]
Therefore, the present invention encompasses any of the
above-mentioned stereoisomers, optical isomers, polymorphs,
tautomers, optional mixtures thereof and the like.
[0047]
The pharmaceutically acceptable salt of compound (I)
includes, inorganic acid addition salts (e.g., salts with
hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric
acid, phosphoric acid and the like), organic acid addition
salts (e.g., salts with methanesulfonic acid, benzenesulfonic
acid, p-toluenesulfonic acid, formic acid, acetic acid,
trifluoroacetic acid, oxalic acid, citric acid, malonic acid,
fumaric acid, glutaric acid, adipic acid, maleic acid,
tartaric acid, succinic acid, mandelic acid, malic acid,
pantothenic acid, methylsulfuric acid and the like), salts
13
CA 02548918 2006-06-09
with amino acids (e.g., salts with glutamic acid, aspartic
acid and the like), and the like.
[0048]
The a-amino acid derivative of the present invention can
be produced by the following method.
[0049]
Scheme 1 shows a production method of a compound (I)
wherein m = 2, n = 0 and X = CH-OH or CH-NH2.
Scheme 1
/o [0050]
R27 Rn
P Step a )P
OH OH
H2N H2N
0 0
(IV) (V)
1 Step b
R27 R27 R2
\
p Step a )p Step c
R26 0R28 Rn 0R28 Rn OH
0 0 0
(VII) (VIII) (VI)
y R1
I Step b (ZR2 Step d
R27 R27
HN
Si
i7 (
le_R2
p Step a )p
0 R28 0 R28 R2 R 1
H2N H2 N
0 R26 N
(IX) OQ N
0
pap
[0051]
wherein R26 is an amino acid-protecting group (e.g., tert-
butoxycarbonyl (hereinafter to be referred to as Boc),
benzyloxycarbonyl (hereinafter to be referred to as Cbz)), R27
is a hydroxyl group or an amino group, R" is alkyl such as
14
CA 02548918 2006-06-09
methyl, ethyl and the like, benzyl and the like, and other
symbols are as defined above.
Step a: a step for producing a compound represented by the
formula (V) or a salt thereof by reducing a compound
represented by the formula (IV) or a salt thereof, producing a
compound represented by the formula (VIII) or a salt thereof
by reducing a compound represented by the formula (VII) or a
salt thereof, or producing a compound represented by the
formula (X) or a salt thereof by reducing a compound
/o represented by the formula (IX) or a salt thereof.
[0052]
The reaction is carried out by catalytic hydrogenation
reaction using a metal catalyst. As the metal catalyst,
palladium or oxide thereof, platinum or oxide thereof, rhodium
or oxide thereof, ruthenium, Raney-nickel and the like are
used, where these metals may be used in combination. In
addition, the metal is supported on an inactive carrier such
as activated carbon, alumina, barium sulfate, calcium
carbonate and the like.
[0053]
As the solvent to be used for the reaction, for example,
alcohol solvent (e.g., methanol, ethanol etc.), hydrocarbon
solvent (e.g., benzene, toluene, hexane, heptane etc.), ethyl
acetate, acetic acid, water and the like can be mentioned and,
where necessary, a mixed solvent thereof can be used.
[0054]
The reaction is carried out under a hydrogen atmosphere
at a normal pressure or high pressure, and the reaction
temperature is about 0 C to 150 C, preferably 0 C to 120 C.
3 [0055]
Step b: a step for producing a compound represented by the
formula (VI) or a salt thereof by protecting an amino group of
a compound represented by the formula (V) or a salt thereof,
or producing a compound represented by the formula (VIII) or a
salt thereof by protecting an amino group of a compound
CA 02548918 2006-06-09
represented by the formula (X) or a salt thereof.
[0056]
When R26 is Boc, as a Boc agent, di-tert-butyl
dicarbonate, 2-tert-butoxycarbonyloxyimino-2-
phenylacetonitrile (Boc-ON), tert-butoxycarbony1-4,6-dimethy1-
2-thiopyrimidine and the like can be used. As the base to be
used for this reaction, an organic base such as triethylamine,
N,N-diisopropylethylamine (hereinafter to be referred to as
DIPEA) and the like, hydroxide of alkali metal or alkaline
earth metal (e.g., sodium hydroxide, potassium hydroxide etc.)
and the like can be mentioned. As the solvent to be used for
the reaction, for example, water, alcohol solvent (e.g.,
methanol, ethanol etc.), ether solvent (e.g., tetrahydrofuran
(hereinafter to be referred to as THF), dioxane etc.) and the
like, and, where necessary, a mixed solvent thereof can be
used.
[0057]
When R26 is Cbz, as a Cbz agent, benzyloxycarbonyl
chloride and the like can be used. In addition, an
introduction method using an active ester such as dibenzyl
dicarbonate, O-benzyloxycarbonyl-N-hydroxysuccinimide and the
like can also be used. As the base to be used for this
reaction, an organic base such as triethylamine, pyridine and
the like, hydroxide of alkali metal or alkaline earth metal
(e.g., sodium hydroxide, potassium hydroxide etc.),
hydrogencarbonate of alkali metal or alkaline earth metal
(e.g., sodium hydrogencarbonate, potassium hydrogencarbonate
etc.) and the like can be mentioned. As the solvent to be used
for the reaction, for example, water, ether solvent (e.g.,
THF, dioxane etc.), ethyl acetate, acetonitrile, N,N-
dimethylformamide (hereinafter to be referred to as DMF) and
the like can be mentioned and, where necessary, a mixed
solvent thereof can be used.
[0058]
Step c: a step for producing a compound represented by the
16
CA 02548918 2006-06-09
formula (VI) or a salt thereof by deprotecting an ester-
protected carboxyl group of a compound represented by the
formula (VIII) or a salt thereof.
[0059]
For the reaction, conventional deprotection reaction for
carboxyl group can be used. As the base to be used, carbonate
of alkali metal or alkaline earth metal (e.g., sodium
carbonate, potassium carbonate etc.), hydroxide of alkali
metal or alkaline earth metal (e.g., sodium hydroxide,
potassium hydroxide etc.) and the like can be mentioned. When
R28 is a benzyl group, deprotection can also be carried out by
a catalytic hydrogenation reaction using a metal catalyst such
as platinum, palladium and the like. As the solvent to be used
for the reaction, for example, alcohol solvent (e.g.,
methanol, ethanol etc.), ether solvent (e.g., THF, dioxane
etc.) and the like can be mentioned and, where necessary, a
mixed solvent with water can be mentioned. The reaction
temperature therefor is about 0 C to 100 C.
[0060]
Step d: a step for producing a compound represented by the
formula (XII) by reacting a compound represented by the
formula (VI) or a salt thereof with a compound represented by
the formula (XI) or a salt thereof.
[0061]
It can be produced by reacting a compound represented by
the formula (XI) or a salt thereof with an acidic compound
represented by the formula (VI) or a reactive derivative
thereof or a salt thereof using a dehydrating condensing agent
in a solvent and, where necessary, in the presence of a base.
As the reactive derivative of the acidic compound, acid
anhydride, active ester (e.g., p-nitrophenyl ester, N-
hydroxysuccinimido ester, pentafluorophenyl ester, 1-
hydroxybenzotriazole ester etc.), acid halide (e.g., acid
chloride, acid bromide etc.), imidazolide, mixed acid
anhydride (e.g., anhydride with methyl carbonate, anhydride
17
CA 02548918 2006-06-09
with ethyl carbonate etc.) and the like can be mentioned. As
the solvent to be used, for example, ether solvent (e.g.,
diethyl ether, THF, dioxane etc.), hydrocarbon solvent (e.g.,
benzene, toluene, hexane, heptane etc.), halogen solvent
(e.g., dichloromethane, dichloroethane, chloroform, carbon
tetrachloride etc.), acetonitrile, DMF and the like can be
mentioned. As the base to be used, an organic base such as
triethylamine, 4-dimethylaminopyridine (hereinafter to be
referred to as DMAP), DIPEA, triethylenediamine, 4-
methylmorpholine and the like, carbonate of alkali metal or
alkaline earth metal (e.g., sodium carbonate, potassium
carbonate etc.), hydrogencarbonate of alkali metal or alkaline
earth metal (e.g., sodium hydrogencarbonate, potassium
hydrogencarbonate etc.), hydroxide of alkali metal or alkaline
earth metal (e.g., sodium hydroxide, potassium hydroxide etc.)
and the like can be mentioned.
[0062]
As the dehydrating condensing agent, for example,
condensing agents to be used for peptide synthesis, and the
like can be mentioned. Specifically, for example,
dicyclohexylcarbodiimide (hereinafter to be referred to as
DCC), N-(3-dimethylaminopropy1)-N'-ethylcarbodiimide
(hereinafter to be referred to as EDC) or hydrochloride
thereof, 2-ethoxy-1-ethoxycarbony1-1,2-dihydroxyquinoline,
carbodiimidazole, diethylphosphoryl cyanide, benzotriazol-1-
yloxytrispyrrolidinophosphonium hexafluorophosphate,
diphenylphosphoryl azide (hereinafter to be referred to as
DPPA), propanephosphinic anhydride, isobutyl chloroformate,
diethylacetyl chloride, trimethylacetyl chloride and the like
can be mentioned. These condensing agents are used alone or in
combination with an activator such as N-hydroxysuccinimide,
hydroxybenzotriazole (hereinafter to be referred to as HOBT),
3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine, DMAP and the
like, preferably HOBT. The compound represented by the formula
(XI) or a salt thereof is used in an amount of about 0.5 to 10
18
. CA 02548918 2006-06-09
mol equivalents, preferably about 1 to 6 mol equivalents, and
the condensing agent is used in an amount of about 0.5 to 10
mol equivalents, preferably about 1 to 5 mol equivalents, both
per 1 mol of a compound represented by the formula (VI) or a
salt thereof. The reaction temperature is about -30 C to 100 C,
preferably -10 C to 80 C, and the reaction time is about 30 min
to 96 hr, preferably 30 min to 48 hr.
[0063]
Scheme 2 shows a production method of compound (I)
wherein X = CH-R3 and R3= -NR7R9.
Scheme 2
[0064]
OH 0,.s02R29
ctf'-1)-5y ______________________________________________ cinyel,
y RI y R1
R
2
R N -
Step e
-"N Z
H H
Step m / 0 0 \
0
/ QM PM
-)L1( )m Step f\ N3
1 Step g
y R 2 H
illf,l)i,,Irn
C Z
...õ.rm R ,NRe
R7 '
y R1
Step i
(MAIO
N Z H n ) p C ZR2
H R26 N
) Step 1
R(:1C-fte
(XIX) H 0
V" NR7R8
Step n R7 Hal(XV) NH2
(XIV)
)rn /tS ep h
-"--(14')in or
y RI R8-Hal (n)
Step
y R1
j
R2
R26
Or 26
o N Z
H H
0
0
R311)t-R31
00/4 (")
OCA
Step k
1 Step o
NR7Re
CLI(-11)jyT1H2nN )P C-N,--Z.-yZRR12
0
(XX)
[0065]
wherein 0S02R29 is a leaving group (e.g., p-toluenesulfonyloxy
19
CA 02548918 2006-06-09
(0Ts), methanesulfonyloxy (OMs), trifluoromethanesulfonyloxy
(0Tf)), Hal is a halogen atom, R3 and R31 are optionally the
same or different and each independently is a hydrogen atom,
alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl,
heteroaryl or heteroarylalkyl, or are optionally bonded to
each other to form heterocycle having at least one nitrogen
atom, and optionally having other further hetero atom(s),
wherein the heterocycle is optionally substituted or condensed
with an aromatic ring optionally having substituent(s), and
other symbols are as defined above.
Step e: a step for producing a compound represented by the
formula (XIII) by sulfonylating a hydroxyl group of a compound
represented by the formula (XII').
[0066]
This reaction can be carried out using a sulfonylating
agent such as methanesulfonyl chloride, p-toluenesulfonyl
chloride, trifluoromethanesulfonyl chloride and the like. In
this event, a suitable base may be co-existent. As the base,
an organic base such as triethylamine, DMAP, DIPEA,
triethylenediamine, 4-methylmorpholine and the like, carbonate
of alkali metal or alkaline earth metal (e.g., sodium
carbonate, potassium carbonate etc.) and the like can be
mentioned. As the solvent to be used for the reaction, for
example, ether solvent (e.g., diethyl ether, THF, dioxane
etc.), halogen solvent (e.g., dichloromethane, dichloroethane,
chloroform, carbon tetrachloride etc.), DMF and the like can
be mentioned. The reaction temperature is about -50 C to 100 C,
preferably -10 C to 80 C, and the reaction time is about 0.1 to
96 hr, preferably 0.1 to 24 hr.
[0067]
Step f: a step for producing a compound represented by the
formula (XIV) by azidating a compound represented by the
formula (XIII).
[0068]
The reaction is carried out using a metal azide (e.g.,
CA 02548918 2006-06-09
sodium azide, lithium azide etc.). As the solvent to be used,
for example, DMF, dimethyl sulfoxide (hereinafter to be
referred to as DMSO), acetonitrile, dichloromethane, water and
the like can be mentioned and, where necessary, a mixed
solvent thereof can be used. As the additive, 18-crown-6 can
also be used. The reaction temperature is about 0 C to 120 C,
and the reaction time is about 30 min to 24 hr.
[0069]
Step g: a step for producing a compound represented by the
formula (XIV) directly from a compound represented by the
formula (XII').
[0070]
The reaction is carried out by reaction with an azidating
agent such as hydrogen azide, DPPA, zinc azide bispyridine
complex and the like in the presence of phosphines such as
triphenylphosphine, tributylphosphine and the like and
azodicarboxylic acid diester. In addition, DPPA may be allowed
to act in the presence of an organic base such as 1,8-
diazabicyclo[5.4.0]-7-undecene (hereinafter to be referred to
as DBU) and the like. As the solvent to be used, for example,
ether solvent (e.g., diethyl ether, THF, dioxane etc.),
hydrocarbon solvent (e.g., benzene, toluene, hexane, heptane
etc.) and the like can be mentioned. The reaction temperature
is about -30 C to 100 C, and the reaction time is about 30 min
to 72 hr.
[0071]
Step h: a step for producing a compound represented by the
formula (XII") or a salt thereof by reducing a compound
represented by the formula (XIV).
[0072]
As this reaction, a catalytic hydrogenation reaction
using a metal catalyst such as palladium, platinum, nickel and
the like, reduction by a metal hydride such as lithium
aluminum hydride and the like, reduction using
triphenylphosphine, thiol, sulfide, diborane or a transition
21
CA 02548918 2006-06-09
metal, and the like can be mentioned, and preferably, a
catalytic hydrogenation reaction using a metal catalyst and a
reaction using triphenylphosphine can be mentioned.
[0073]
Step i: a step for producing a compound represented by the
formula (XII") or a salt thereof by phthalimidating a hydroxyl
group of a compound represented by the formula (XII') or a
salt thereof and then hydrolyzing the same.
[0074]
In this reaction, phthalimide or a salt thereof (e.g.,
potassium salt etc.) is reacted in the presence of
azodicarboxylic acid diesters (e.g., diethyl azodicarboxylate,
diisopropyl azodicarboxylate etc.) and phosphines (e.g.,
triphenylphosphine, tributylphosphine etc.). The amount of the
compound to be used is about 1 to 10 molar equivalents,
preferably about 3 to 5 molar equivalents, of phthalimide or a
salt thereof relative to the compound represented by the
formula (XII') or a salt thereof. The amount of each of the
azodicarboxylates and phosphines to be used is about 1 to 10
molar equivalents, preferably about 3 to 5 molar equivalents,
relative to the compound represented by the formula (XII') or
a salt thereof. It is advantageous to use a solvent inert to
the reaction. The solvent is not particularly limited as long
as the reaction proceeds and, for example, ether solvent
(e.g., diethyl ether, THF, dioxane etc.), hydrocarbon solvent
(e.g., benzene, toluene, hexane, heptane etc.), halogen
solvent (e.g., dichloromethane, dichloroethane, chloroform
etc.), acetonitrile, DMF and the like can be mentioned and,
where necessary, a mixed solvent thereof can be used.
3 [0075]
The phthalimide compound thus produced can be led to a
compound represented by the formula (XII") or a salt thereof
by hydrolysis using hydrazine. As the solvent to be used for
the reaction, for example, water, alcohol solvent (e.g.,
methanol, ethanol etc.), ether solvent (e.g., THF, dioxane
22
CA 02548918 2006-06-09
etc.) and the like can be mentioned and, where necessary, a
mixed solvent thereof can be used.
[0076]
Step j: a step for producing a compound represented by the
formula (XVII) or a salt thereof by reacting a compound
represented by the formula (XII") or a salt thereof with a
compound represented by the formula (XV) or a compound
represented by (XV').
[0077]
/o
The reaction is carried out in the presence of an organic
base such as triethylamine, DIPEA and the like, preferably
DIPEA, in a solvent inert to the reaction such as N-methy1-2-
pyrrolidone, DMF, THF and the like, at 0 C to a temperature
near the boiling point of the solvent, preferably 0 C to 80 C.
[0078]
Step k: a step for producing a compound represented by the
formula (XVII) or a salt thereof by reacting a compound
represented by the formula (XII") or a salt thereof with a
compound represented by the formula (XVI), followed by
reduction.
[0079]
The reductive amination reaction can be carried out, for
example, by reacting a compound represented by the formula
(XII") or a salt thereof with a compound represented by the
formula (XVI) in a solvent such as ether solvent (e.g.,
diethyl ether, THF, dioxane etc.), hydrocarbon solvent (e.g.,
benzene, toluene, hexane, heptane etc.), halogen solvent
(e.g., dichloromethane, dichloroethane, chloroform, carbon
tetrachloride etc.), alcohol solvent (e.g., methanol, ethanol,
n-propanol, isopropanol etc.), acetonitrile, DMF and the like,
or in a mixed solvent thereof as necessary, in the presence of
a metal hydride complex compound (e.g., composite hydride
compound such as sodium borohydride, sodium cyanoborohydride,
sodium triacetoxyborohydride and the like, diborane etc.) and,
where necessary, an acidic catalyst (e.g., acetic acid, p-
23
CA 02548918 2006-06-09
toluenesulfonic acid, boron trifluoride diethyl ether complex
etc.). The compound represented by the formula (XVI) is used
in an amount of about 0.5 to 10 molar equivalents, preferably
about 1 to 5 molar equivalents, and the metal hydride complex
compound is used in an amount of about 0.5 to 10 molar
equivalents, preferably about 1 to 5 molar equivalents, both
relative to a compound represented by the formula (XII") or a
salt thereof. The reaction temperature is -20 C to 200 C,
preferably 0 C to 100 C, and the reaction time is about 0.5 to
I 96 hr, preferably 0.5 to 24 hr.
[0080]
A compound represented by the formula (XVII) wherein R7
and R8 are the same or different or a salt thereof can be
produced by repeating Step j or k as necessary.
[0081]
Step 1: a step for producing a compound represented by the
formula (XVII) or a salt thereof by activating a compound
represented by the formula (XII') and then reacting the
compound with an amine represented by the formula (XVIII) or a
salt thereof.
[0082]
The compound represented by the formula (XII') or a salt
thereof can be activated with about 1 to 10 molar equivalents,
preferably about 1 to 5 molar equivalents, of a halogenating
reagent such as thionyl chloride, phosphorus trichloride,
phosphorus pentachloride, phosphorus tribromide, phosphorus
pentabromide, carbon tetrabromide-triphenylphosphine and the
like in a solvent, or with about 1 to 10 molar equivalents,
preferably about 1 to 5 molar equivalents, of p-
toluenesulfonyl chloride, methanesulfonyl chloride,
trifluoromethanesulfonic anhydride and the like in the
presence of a base [organic base such as triethylamine, DMAP,
DIPEA, triethylenediamine, 4-methylmorpholine and the like,
carbonate of alkali metal or alkaline earth metal (e.g.,
sodium carbonate, potassium carbonate etc.), hydrogencarbonate
24
CA 02548918 2006-06-09
of alkali metal or alkaline earth metal (e.g., sodium
hydrogencarbonate, potassium hydrogencarbonate etc.) and the
like. The solvent used here is, for example, acetonitrile,
halogen solvent (e.g., dichloromethane, dichloroethane,
chloroform etc.), ether solvent (e.g., diethyl ether, THF,
dioxane etc.), hydrocarbon solvent (e.g., benzene, toluene,
hexane, heptane etc.) and the like, and the reaction
temperature is about -20 C to 100 C, preferably about 0 C to
60 C. The activated compound or a salt thereof may be reacted
/o with potassium iodide, sodium iodide and the like in a solvent
such as acetonitrile, DMF and the like to give an iodide. The=
compound thus activated or a salt thereof is reacted with
about 1 to 10 molar equivalents, preferably about 1 to 5 molar
equivalents, of an amine represented by the formula (XVIII) or
a salt thereof in a solvent to give a compound represented by
the formula (XVII) or a salt thereof. The solvent used here
is, for example, acetonitrile, halogen solvent (e.g.,
dichloromethane, dichloroethane, chloroform etc.), ether
solvent (e.g., diethyl ether, THF, dioxane etc.), hydrocarbon
solvent (e.g., benzene, toluene, hexane, heptane etc.), DMF,
N,N-dimethylacetamide and the like, and the reaction
temperature is about -20 C to 150 C, preferably about 0 C to
100 C. Where necessary, a base [organic base such as
triethylamine, DMAP, DIPEA, triethylenediamine, 4-
methylmorpholine and the like, carbonate of alkali metal or
alkaline earth metal (e.g., sodium carbonate, potassium
carbonate etc.), hydrogencarbonate of alkali metal or alkaline
earth metal (e.g., sodium hydrogencarbonate, potassium
hydrogencarbonate etc.) and the like] may be used.
[0083]
In addition, a compound represented by the formula (XII')
and an amine represented by the formula (XVIII) or a salt
thereof may be subjected to Mitsunobu reaction or a
modification thereof to give a compound represented by (XVII)
or a salt thereof. This reaction is carried out in the
CA 02548918 2006-06-09
presence of azodicarboxylic acid diesters (e.g., diethyl
azodicarboxylate, 1,1'-(azodicarbonyl)dipiperidines) and
phosphines (e.g., triphenylphosphine, tributylphosphine etc.).
The amount of the compound to be used is about 1 to 5 molar
equivalents, preferably about 1 to 2 molar equivalents, of an
amine represented by the formula (XVIII) or a salt thereof
relative to the compound represented by the formula (XII') or
a salt thereof. The amount of each of the azodicarboxylic acid
diesters and phosphines to be used is about 1 to 5 molar
equivalents, preferably about 1 to 2 molar equivalents,
relative to the compound represented by the formula (XII') or
=
a salt thereof. It is advantageous to use a solvent inert to
the reaction. The solvent is not particularly limited as long
as the reaction proceeds and, for example, ether solvent
(e.g., diethyl ether, THF, dioxane etc.), hydrocarbon solvent
(e.g., benzene, toluene, hexane, heptane etc.), halogen
solvent (e.g., dichloromethane, dichloroethane, chloroform
etc.), acetonitrile, DMF and the like can be mentioned.
[0084]
Step m: a step for producing a compound represented by the
formula (XIX) by oxidizing a compound represented by the
formula (XII').
[0085]
Examples of the oxidization reaction include a method
using an oxidant such as pyridinium chlorochromate, pyridinium
dichromate, manganese dioxide and the like, and DMSO
oxidization such as DMSO-oxalyl chloride, DMSO-acetic
anhydride, DMSO-trifluoroacetic anhydride, DMSO-pyridine
sulfur trioxide complex and DMSO-DCC, -EDC and the like using
dichloroacetic acid as a catalyst. As the solvent, halogen
solvent (e.g., dichloromethane, dichloroethane, chloroform
etc.), ether solvent (e.g., diethyl ether, THF, dioxane etc.),
DMF and the like can be mentioned. In addition, a method
comprising reaction with an aqueous sodium hypochlorite
solution using 2,2,6,6-tetramethyl-1-piperidinyloxy free
26
CA 02548918 2006-06-09
radical as a catalyst in the presence of sodium bromide in
ethyl acetate or toluene, and the like can be mentioned. By
the reaction with 1 to 10 molar equivalents, preferably 1 to 3
molar equivalents, of an oxidant and the like, a compound
represented by the formula (XIX) or a salt thereof can be
obtained. The reaction temperature is about -78 C to 100 C,
preferably -40 C to 60 C, and the reaction time is about 30 min
to 24 hr, preferably about 1 to 15 hr.
[0086]
Step n is performed in the same manner as in Step k.
[0087]
Step o: a step for producing a compound represented by the
formula (XX) or a salt thereof by deprotecting a compound
represented by the formula (XVII) or a salt thereof.
[0088]
In this reaction, when the protecting group R26 is a Boc
group, deprotection can be performed using an acid such as
hydrochloric acid, sulfuric acid, trifluoroacetic acid, p-
toluenesulfonic acid, methanesulfonic acid and the like. In
this case, these acids are dissolved in an organic solvent or
water and the deprotection can be carried out at about -50 C to
50 C. This reaction can be carried out, for example, in a
solvent such as ether solvent (e.g., THF, dioxane etc.),
halogen solvent (e.g., dichloromethane, dichloroethane,
chloroform etc.), alcohol solvent (e.g., methanol, ethanol
etc.), acetonitrile, ethyl acetate and the like. When the
protecting group R26 is a Cbz group, deprotection can be
performed with an acid, or by a catalytic hydrogenation
reaction using a metal catalyst such as palladium and the
like. The catalytic hydrogenation reaction can be carried out
in a solvent such as ether solvent (e.g., THF, dioxane etc.),
alcohol solvent (e.g., methanol, ethanol etc.), ethyl acetate
and the like. The reaction temperature is about 0 C to 100 C
and a hydrogen gas can also be used at normal pressure or
under pressurization, or a combination of reagents such as
27
CA 02548918 2006-06-09
formic acid-ammonium formate can also be used. The reaction
using an acid may be a reaction with hydrobromic acid-acetic
acid, or can be carried out using, for example,
trifluoroacetic acid or trifluoromethanesulfonic acid,
preferably trifluoromethanesulfonic acid, in, where necessary,
a solvent inert to the deprotection reaction such as halogen
solvent (e.g., dichloromethane, dichloroethane, chloroform
etc.) and the like in the presence of thioanisole or anisole.
[0089]
Compound 000 obtained here can be taken out as a base or
a salt with a suitable acid. The suitable acid includes, for
example, hydrochloric acid, sulfuric acid, trifluoroacetic
acid, p-toluenesulfonic acid, methanesulfonic acid, acetic
acid and the like.
[0090]
Scheme 3 shows a production method of compound (I)
wherein X = CH-R3, and R3 = -NR8COR1 .
Scheme 3
[0091]
0 0
Rg
NHRg Rgss'NARla Rl
1110)m R10COOH
R1
rn
A ,R1 or
,A R1 A
n p Z's R2 R 1 C0CI
10111)1.-rn't)p
1026
NN
" '`N R26
Step p z Step q H2N.--y
H
0 0 0
(XXI) pom pom
[0092]
wherein each symbol is as defined above.
A compound represented by the formula (XXI) or a salt
thereof is the same as the compound represented by the formula
(XII") obtained in Scheme 2 or a salt thereof, or a compound
represented by the formula (XVII) wherein one of R7 and R8 is a
hydrogen atom or a salt thereof.
28
CA 02548918 2006-06-09
[0093]
Step p: a step for producing an amide compound represented by
the formula (XXII) or a salt thereof by acylating a compound
represented by the formula (XXI) or a salt thereof.
[0094]
The reaction is carried out using R1 C0C1 or by
converting R1 CO2H to an acid halide with thionyl chloride,
thionyl bromide and the like, or to a mixed acid anhydride
with pivaloyl chloride, isobutyl chloroformate and the like.
As the base to be used for the reaction, an organic base such
as triethylamine, DMAP, DIPEA, triethylenediamine, 4-
methylmorpholine and the like can be mentioned, and as the
solvent to be used, for example, ether solvent (e.g., diethyl
ether, THF, dioxane etc.), hydrocarbon solvent (e.g., benzene,
toluene, hexane etc.), halogen solvent (e.g., dichloromethane,
dichloroethane, chloroform etc.), ethyl acetate, chloroform,
DMF, DMSO, hexamethylphosphoramide and the like can be
mentioned. This reaction is generally carried out at about 0 C
to 120 C for about 10 min to 10 hr.
[0095]
The reaction with R1 CO2H can be carried out under the
conditions shown in Scheme 1, Step d.
[0096]
Step q is performed in the same manner as in Scheme 2,
Step o.
[0097]
Scheme 4 shows a production method of compound (I)
wherein X - CH-R3 and R3= -NR11CONR12R13.
Scheme 4
[0098]
29
CA 02548918 2006-06-09
0 0
R" R"
NHR" NeR" Nee
1110)m 11111)m 1111)m
y R1 y R1 zy R1
n )p \ZR2 _________________________ n )p Z-R2 = n )p Z7R2
R26 z Step r RM`N Step $ H2N
0 0 0
WAO p00/) 00WD
[0099]
wherein each symbol is as defined above.
A compound represented by the formula (XXIV) is the same
as the compound represented by the formula (XII") obtained in
Scheme 2 or a salt thereof, or a compound represented by the
formula (XVII) wherein one of R7 and R8 is a hydrogen atom or a
salt thereof.
[0100]
/o Step s: a step for producing a urea compound represented by
the formula (XXV) by reacting a compound represented by the
formula (XXIV) or a salt thereof.
[0101]
The reaction can be carried out using isocyanate such as
R12-NCO and the like. The reaction is carried out in a solvent
inert to the reaction such as toluene, chloroform,
dichloromethane, THF and the like generally at a temperature
of -20 C to 80 C, preferably 0 C to 25 C.
[0102]
In addition, for example, a method using
carbodiimidazole, phosgene, diphosgene (trichloromethyl
chloroformate) or triphosgene [bis(trichloromethyl)carbonate]
and the like with an amine represented by R12R13NH and a
tertiary organic base such as triethylamine and the like may
be employed.
[0103]
Step s is performed in the same manner as in Scheme 2,
Step o.
[0104]
CA 02548918 2006-06-09
Scheme 5 shows a production method of compound (I)
wherein X = CH-R3 and R3= -NR14S02R15.
Scheme 5
[0105]
14
NHR14-SO2R15 R14 SO R15
m 1111)M)m
y R1 y ,R1 1
n )p n )p (ZR2 ________________ n )p eYFR2
==õ,
-z Step t 0'NI Step u H2N N
0 0
(Xoam) 000m (XXIX)
[0106]
wherein each symbol is as defined above.
The compound represented by the formula (XXVII) or a salt
thereof is the same as the compound represented by the formula
(XII") obtained in Scheme 2 or a salt thereof, or a compound
represented by the formula (XVII) wherein one of R7 and R8 is a
hydrogen atom or a salt thereof.
[0107]
Step t: a step for producing a sulfonamide compound
represented by the formula (XXVIII) by sulfonylating a
compound represented by the formula (XXVII) or a salt thereof.
[0108]
The reaction is carried out using sulfonyl chloride such
as R15-S02C1 and the like in the presence of an organic base
such as triethylamine, pyridine and the like or an inorganic
base such as carbonate of alkali metal or alkaline earth metal
(e.g., sodium carbonate, potassium carbonate etc.), hydroxide
of alkali metal or alkaline earth metal (e.g., sodium
hydroxide, potassium hydroxide etc.) and the like in a solvent
inert to the reaction such as water, toluene, chloroform,
dichloromethane, THF and the like generally at a temperature
of about -20 C to 80 C.
[0109]
Alternatively, a method comprising reacting a compound
represented by the formula (XXVII) with sulfuryl chloride in
31
CA 02548918 2006-06-09
the presence of a tertiary organic base such as triethylamine
and the like in a solvent inert to the reaction such as
chloroform, dichloromethane, THF and the like to give
sulfamoyl chloride, which is then reacted with an aryl
compound in the presence of a Lewis acid such as aluminum
chloride and the like may be employed.
[0110]
Step u is performed in the same manner as in Scheme 2,
Step o.
/0 [0111]
Scheme 6 shows a different production method of a
compound represented by the formula (XVII) or a salt thereof.
This production method is useful for a compound wherein both R7
and R8 are not hydrogen atoms.
Scheme 6
[0112]
OH NR1R8 NR/R8
I/11)m
n )p
n )p
R26 l Step v
R26
Step w
26
."\I1 CO2R28 N----...0O2R28 R CO2H
(XXX) (XXXI) (XXXII)
y R1
R2
HN Step x
(XI)
NR7R8
)rn
Ri
)p ( R2
0
(XVm)
[0113]
wherein each symbol is as defined above.
32
= CA 02548918 2006-06-09
Step v is the same as the conversion method of the
compound represented by the formula (XII') to a compound
represented by the formula (XVII) or a salt thereof, as shown
in Scheme 2.
[0114]
Step w is performed in the same manner as in Scheme 1,
Step c.
[0115]
Step x is performed in the same manner as in Scheme 1,
Step d.
[0116]
The compound represented by the formula (XXIII) as shown
in Scheme 3, the compound represented by the formula (XXVI) as
shown in Scheme 4, and a compound represented by the formula
(XXIX) as shown in Scheme 5 can be produced by the route shown
in Scheme 6.
[0117]
Scheme 7 shows a production method of compound (I)
wherein X = N-R4.
Scheme 7
[0118]
R4 R4
R4 0
)
flm
(Me0)2 PT ), Step y Step z
cplo + R28,,)p
26
N -CO2R28 R28CO2Rae 0
-CO2H
(XXXIII) (XXXIV) (xxxv)
(X)OCVI)
y R1
N/4--R2
Step aa
(XI)
R4 R4
N
R12 Step ab
y
rrt )10 ZR
28 nP Qc¨R2
R
N
0
(XXXVIII)
(XXXV1I)
33
CA 02548918 2006-06-09
= 27103-500
[0119]
wherein each symbol is the as defined above.
Step y: a step for producing a compound represented by the
formula (XXXV) or a salt thereof by reacting a compound
represented by the formula (XXXIII) and a compound represented
by the formula (XXXIV), followed by reduction.
[0120]
A coupling reaction between a compound represented by the
formula (XXXIII) and a compound represented by the formula
(XXXIV) is carried out in the presence of a bulky organic base
such as DBU, DIPEA, potassium tert-butoxide and the like in a=
solvent inert to the reaction such as chloroform,
dichloromethane, THF, acetonitrile and the like. As the
additive, lithium chloride or 18-crown-6 can also be used. The
reaction temperature is about -80 C to 80 C, preferably -80 C to
C, and the reaction time is about 1 to 72 hr, preferably 1
to 24 hr.
[0121] fl
The unsaturated compound thus obtained is subjected to a
20 catalytic hydrogenation reaction using a transition metal
catalyst to reduce the carbon-carbon double bond. As the
transition metal catalyst to be used, for example, palladium
catalyst [for example, palladium carbon,
tetrakis(triphenylphosphine)palladium, dichloro
25 bis(triphenylphosphine)palladium, palladium oxide etc.] can be
mentioned. The catalytic hydrogenation reaction is carried out
in a solvent such as alcohol solvent (e.g., methanol, ethanol
etc.), acetic acid and the like, and a catalytic amount of an
inorganic acid such as hydrochloric acid and the like may be
added. This reaction is carried out using a hydrogen gas at
normal pressure or under pressurization at a reaction
temperature of about 0 C to 100 C. In addition, the
enantioselective catalytic hydrogenation reaction of the
unsaturated compound can be carried out by the method of Burk
34
CA 02548918 2006-06-09
et al. [Burk et al., J. Am. Chem. Soc., vol. 117, 9375-9376
(1995)].
[0122]
Step z is performed in the same manner as in Scheme 1,
Step c.
[0123]
Step aa is performed in the same manner as in Scheme 1,
Step c.
[0124]
Step ab is performed in the same manner as in Scheme 2,
Step o.
[0125]
Scheme 8 shows a different production method of a
compound represented by the formula (XXXVI) or a salt thereof.
Scheme 8
[0126]
R4 R4
1")
R4 0 .(')m
Step ac Bn
)p
( fi)m 4. (mew)2 k i? Step ad
CO2R28 CO2H Bn
*rr-C-'41
-.1(9 0
0
(XXXIII) (XXXI X) (X XXX) HN
(XXXXII)
0
(XXXXI)
Step ae
R4 R4 R4
Bn )
Step ag Step af Bn
)p = )-;-\
mm 0
0
R26 N H
H 0 0 0
0
(XXXVI) (XXXX IV) (XXXXIII)
[0127]
wherein each symbol is as defined above.
Step ac is performed in the same manner as in Scheme 7,
Step y and Scheme 1, Step c.
[0128]
Step ad: a step for producing a compound represented by the
CA 02548918 2006-06-09
formula (XXXXII) or a salt thereof by condensation reacting a
compound represented by the formula (XXXX) or a salt thereof
with a chiral auxiliary group represented by the formula
(XXXXI).
[0129]
According to this method, a carboxyl group of a compound
represented by the formula (XXXX) or a salt thereof is
activated and the compound is reacted with a chiral auxiliary
group represented by the formula (XXXXI). The carboxyl group
lo can be activated, for example, by reacting with thionyl
chloride or acid chloride such as pivaloyl chloride and the
like in the presence of an organic base such as triethylamine
and the like. The reaction is carried out in a solvent inert
to the reaction such as THF and the like. Lithium chloride is
added to the carboxyl group thus activated and reacted
therewith a chiral auxiliary group represented by the formula
(XXXXI). The reaction temperature is about -80 C to 80 C,
preferably -80 C to 30 C, and the reaction time is about 1 to
72 hr, preferably 1 to 24 hr.
[0130]
Step ae: a step for producing a compound represented by the
formula (XXXXIII) or a salt thereof by azidation reacting a
compound represented by the formula (XXXXII) or a salt
thereof.
[0131]
The stereoselective azidation reaction can be carried out
by the method of Evans et al. [Evans et al., J. Am. Chem.
Soc., vol. 112, 4011-4030 (1990)]. For example, a compound
represented by the formula (XXXXII) or a salt thereof is
converted to an enolate thereof salt with an alkali metal base
such as potassium bis(trimethylsilyl)amide and the like in a
solvent inert to the reaction such as THF and the like, which
is then reacted with 2,4,6-triisopropylbenzenesulfonyl azide
and treated with acetic acid to give an azide compound. The
reaction temperature is about -80 C to 80 C, preferably -80 C to
36
CA 02548918 2006-06-09
30 C, and the reaction time is about 1 to 72 hr, preferably 1
to 24 hr.
[0132]
Step af is performed in the same manner as in Scheme 2,
Step h and Scheme 1, Step b.
[0133]
Step ag: a step for producing a compound represented by the
formula (XXXVI) or a salt thereof by hydrolyzing a compound
represented by the formula (XXXXIV) or a salt thereof.
[0134]
Oxazolidinone can be hydrolyzed with a base such as
lithium hydroxide aqueous solution and the like. As the
solvent to be used, for example, alcohol solvent (e.g.,
methanol, ethanol etc.), ether solvent (e.g., THF, dioxane
etc.), or, where necessary, a mixed solvent thereof can be
used. The reaction temperature is about 0 C to 100 C.
[0135]
While a method using a chiral auxiliary group represented
by the formula (XXXXI) has been shown here, other chiral
auxiliary groups can also be used according to the method of
Ho et al. [J. Org. Chem., vol. 60, 2271-2273 (1995)].
[0136]
In addition, a compound represented by the formula
(XXXVIII) can also be produced by hydrolyzing oxazolidinone of
a compound represented by the formula (XXXXIII) or a salt
thereof, condensing with a compound represented by the formula
(XI) or a salt thereof and converting an azido group to an
amino group.
[0137]
The a-amino acid derivative of the formula (I) of the
present invention produced in this manner can be obtained at
an optional purity by applying a known separation and
purification means as necessary, such as concentration,
extraction, chromatography, reprecipitation, recrystallization
and the like.
37
CA 02548918 2006-06-09
[0138]
The a-amino acid derivative of the formula (I) can be
prepared into an acid addition salt as necessary with an
inorganic acid such as hydrochloric acid, hydrobromic acid,
hydriodic acid, sulfuric acid, phosphoric acid and the like,
an organic acid such as methanesulfonic acid, benzenesulfonic
acid, p-toluenesulfonic acid, formic acid, acetic acid,
trifluoroacetic acid, oxalic acid, citric acid, malonic acid,
fumaric acid, glutaric acid, adipic acid, maleic acid,
/o tartaric acid, succinic acid, mandelic acid, malic acid,
pantothenic acid, methylsulfuric acid and the like, or an
amino acid such as glutamic acid, asparagine acid and the
like. In addition, it is also present as a solvate such as
hydrate and the like.
[0139]
The compound represented by the formula (I) or a
pharmacologically acceptable salt of the present invention has
a superior DPP-IV inhibitory action in mammals (e.g., human,
monkey, dog, cat, rat and the like).
[0140]
Therefore, the compound represented by the formula (I)
and a pharmacologically acceptable salt thereof of the present
invention are useful as DPP-IV inhibitors and useful for the
prophylaxis or treatment of various diseases relating to DPP-
IV inhibitors, for example, for the prophylaxis or treatment
of diseases where GLP-1 is considered to be related (e.g.,
diabetes, obesity and the like), and the like.
[0141]
The compound represented by the formula (I) of the
present invention can be administered to the same subject
together with other therapeutic drug for diabetes, therapeutic
drug for diabetic complications, anti-hyperlipidemic agent,
antihypertensive agent and the like at the same time or time
lag. As used herein, examples of the therapeutic drug for
diabetes include insulin sensitivity increasing agent, a-
38
CA 02548918 2006-06-09
glucosidase inhibitor, biguanide agent and the like. Examples
of the therapeutic drug for diabetic complications include
aldose reductase therapeutic agent. As the anti-hyperlipidemic
agent, statin compound, which is a cholesterol synthetase
inhibitor, squalene synthetase inhibitor, fibrates having
triglyceride lowering action, and the like can be mentioned.
As the antihypertensive agent, calcium antagonist, angiotensin
converting enzyme inhibitor, angiotensin II antagonist and the
like can be mentioned.
/o [0142]
When the compound of the present invention is used on
combination with multiple agents, the mixing ratio thereof can
be appropriately determined depending on the subject of
administration, age and body weight of the administration
subject, symptom, administration time, dosage form,
administration method, combination and the like.
[0143]
When the compound represented by the formula (I) or an
acid addition salt thereof of the present invention is used as
the aforementioned pharmaceutical agent, it is used on its own
or admixed with an appropriate pharmacologically acceptable
carrier, an excipient, a diluent and the like, and
administered orally or parenterally in the form of powder,
granule, tablet, capsule, injection and the like. The above-
mentioned preparation contains an effective amount of a
compound represented by the formula (I) or a pharmacologically
acceptable salt thereof.
[0144]
While the dose of a compound represented by the formula
(I) or a pharmacologically acceptable salt thereof varies
depending on the administration route, target disease,
symptom, body weight and age of patients, and the compound to
be used, it can be determined as appropriately according to
the administration object. Generally, when orally administered
to an adult, 0.01-1000 mg/kg body weight/day, preferably 0.05-
39
CA 02548918 2006-06-09
500 mg/kg body weight/day, is preferably administered once a
day or in several doses a day.
[0145]
The present invention is explained in detail by
referring to Reference Examples and Examples, which are not
to be construed as limitative.
[0146]
H-NMR was measured at 300 MHz. The chemical shift of
H-NMR relative delta (8) value was expressed in parts per
million (ppm) using tetramethylsilane (TMS) as the internal
standard. For the coupling constant, obvious multiplicity is
shown in hertz (Hz) using s (singlet), d (doublet), t
(triplet), m (multiplet), dd (doublet of doublets), brs (broad
singlet) and the like. Thin-layer chromatography used was
manufactured by Merck, and column chromatography was carried
out using silica gel manufactured by Fuji silysia chemical.
[0147]
For drying organic solutions in extraction, anhydrous
sodium sulfate or anhydrous magnesium sulfate was used, unless
particularly indicated.
[0148]
The piperazine compounds and piperidine compound, which
are the starting materials shown in Examples, were synthesized
by the method described in W002/14271.
Example 1
3-((S)-2-amino-2-(trans-4-[4-(5-cyano-2-pyridiny1)-1-
piperaziny1]-1-cyclohexyllacety1)-1,3-thiazolidine
[0150]
cxe4N /NS
NC¨Q¨InN w L_I
[0151]
(1) 4-Hydroxy-L-phenylglycine (21.56 g) was dissolved in water
(250 mL) and 3 mol/L aqueous sodium hydroxide solution (43
mL). Raney-nickel (130 g) was added to conduct hydrogenation
reaction under heating at 80 C and 7.0 kgf/cm2. After 3 hr, the
CA 02548918 2006-06-09
=
reaction mixture was filtered, and the solid was washed with
water. The filtrate was concentrated under reduced pressure to
200 mL. 1,4-Dioxane (150 mL) and triethylamine (32 mL) were
added to the concentrated solution, di-tert-butyl dicarbonate
(33.8 g) was added under ice-cooling, and the mixture was
stirred at room temperature for 20 hr. The organic solvent was
evaporated from the reaction mixture, and 2 mol/L hydrochloric
acid (155 mL) was poured thereinto under ice-cooling to adjust
the mixture to pH 2. Sodium chloride was added to saturation
and the mixture was extracted 4 times with ethyl acetate. The
extract was dried and concentrated under reduced pressure. THF
(350 mL) and 1,3-thiazolidine (13.8 g) were added to the
residue, HOBT (30.40 g) and EDC hydrochloride (29.7 g) were
successively added under ice-cooling, and the mixture was
stirred at room temperature for 12 hr. The reaction mixture
was concentrated, and saturated aqueous sodium
hydrogencarbonate solution was added to the concentrate. The
mixture was extracted with chloroform and the extract was
dried. The solvent was evaporated under reduced pressure and
the residue was purified by silica gel chromatography to give
3-[(S)-2-tert-butoxycarbonylamino-3-(4-hydroxy-1-
cyclohexyl)acety1]-1,3-thiazolidine (41.66 g, yield 93.8%) as
a white solid.
[0152]
(2) The above-mentioned compound (32.98 g) was dissolved in
DIPEA (70 mL), dichloromethane (70 mL) and DMSO (270 mL).
While maintaining the liquid temperature at 20 C, pyridine
sulfur trioxide complex (25.93 g) was added and the mixture
was stirred for 3 hr. Under ice-cooling, 10% citric acid
aqueous solution was added to the reaction mixture, and the
mixture was extracted with toluene. The extract was washed
with water and saturated brine and dried. The solvent was
evaporated under reduced pressure and the residue was purified
by silica gel chromatography to give 3-[(S)-2-tert-
butoxycarbonylamino-2-(4-oxo-1-cyclohexyl)acety1]-1,3-
41
CA 02548918 2006-06-09
thiazolidine (22.10 g, yield 67.4%) as a colorless highly
viscose oil.
1H-NMR (CDC13) 8 1.43 (9H, s), 1.48-1.68 (2H, m), 1.95-2.18
(3H, m), 2.25-2.50 (4H, m), 3.04 (1H, t, J = 6.3 Hz), 3.12
(1H, t, J = 6.3 Hz), 3.70-4.12 (2H, m), 4.38-4.78 (3H, m),
5.29 (1H, d, J = 9.2 Hz).
[0153]
(3) The above-mentioned compound (630 mg) and 1-(5-cyano-2-
pyridyl)piperazine (381 mg) were dissolved in chloroform (8
/o mL), sodium triacetoxyborohydride (780 mg) was added, and the
mixture was stirred at room temperature for 22 hr. Saturated .
aqueous sodium hydrogencarbonate solution was added to the
reaction mixture, and the mixture was extracted with
chloroform. The extract was washed with saturated brine and
dried. The solvent was evaporated under reduced pressure and
the residue was purified by silica gel chromatography to give
3-((S)-2-tert-butoxycarbonylamino-2-{trans-4-[4-(5-cyano-2-
pyridy1)-1-piperaziny1]-1-cyclohexyl}acetyl)-1,3-thiazolidine
as a pale-yellow amorphous trans form (604 mg, yield 63.8%),
and a white amorphous cis form (344 mg, yield 36.2%).
[0154]
(4) The above-mentioned trans form (596 mg) was dissolved in
dichloromethane (5 mL), trifluoroacetic acid (10 mL) was added
under ice-cooling, and the mixture was stirred for 3 hr. The
reaction mixture was concentrated under reduced pressure,
saturated aqueous sodium hydrogencarbonate solution was added
to the residue, and the mixture was extracted with chloroform.
The extract was washed with saturated brine and dried. The
solvent was evaporated under reduced pressure, and the residue
was purified by silica gel chromatography and crystallized
from ethyl acetate to give the title compound (270 mg, yield
56.1 %) as a white powder.
1H-NMR (CDC13) 8 1.38-1.95 (9H, m), 2.18-2.25 (1H, m), 2.50-
2.62 (4H, m), 3.02 (1H, t, J = 6.5 Hz), 3.11 (1H, t, J = 6.2
Hz), 3.38-3.48 (1H, m), 3.62-3.98 (6H, m), 4.51-4.68 (2H, m),
42
CA 02548918 2006-06-09
6.59 (1H, d, J = 9.0 Hz), 7.60 (1H, dd, J = 2.2, 9.0 Hz), 8.40
(1H, d, J = 2.2 Hz).
Example 2
3-((S)-2-amino-2-{cis-4-[4-(5-cyano-2-pyridy1)-1-piperaziny1]-
1-cyclohexyllacety1)-1,3-thiazolidine
[0156]
0
N/NS
-N H H NH2
[0157]
The title compound (83 mg, yield 26%) was obtained as a
white powder using the cis form (384 mg) of Example 1 (3) and,
in the same manner as in Example 1 (4).
1H-NMR (CDC13) 8 1.02-1.37 (4H, m), 1.42-1.75 (2H, m), 1.88-
2.02 (3H, m), 2.23-2.36 (1H, m), 2.58-2.68 (4H, m), 3.02 (1H,
t, J = 6.3 Hz), 3.10 (1H, t, J = 6.1 Hz), 3.34 (1H, dd, J =
6.1, 10.8 Hz), 3.62-3.98 (6H, m), 4.46-4.70 (2H, m), 6.58 (1H,
d, J = 8.9 Hz), 7.59 (1H, dd, J = 2.3, 8.9 Hz), 8.40 (1H, d, J
= 2.3 Hz).
Example 3
3-((S)-2-amino-2-{trans-4-[4-(3-chloro-5-trifluoromethyl-2-
pyridy1)-1-piperaziny1]-1-cyclohexyllacety1)-1,3-thiazolidine
[0159]
a 0
N/NS
F3C-
-N H __ 1-1 NH2
[0160]
(1) Using the product (514 mg) resulting from Example 1 (2)
and 1-(3-chloro-5-trifluoromethy1-2-pyridyl)piperazine (438
mg) and in the same manner as in Example 1 (3), 3-((S)-2-tert-
butoxycarbonylamino-2-{4-[4-(3-chloro-5-trifluoromethy1-2-
pyridiny1)-1-piperaziny1]-1-cyclohexyllacety1)-1,3-
thiazolidine was obtained as a white amorphous trans form (490
mg, yield 55.2%) and a white amorphous cis form (254 mg, yield
28.6%).
43
CA 02548918 2006-06-09
[0161]
(2) The title compound (80 mg, yield 20%) was obtained as a
white powder using the above-mentioned trans form (484 mg) and
in the same manner as in Example 1 (4).
1H-NMR (DMSO-d0 8 1.22-1.86 (9H, m), 2.05-2.27 (2H, brs), 2.57
(4H, s), 2.98 (1H, t, J = 6.4 Hz), 3.04-3.13 (1H, m), 3.2-4.0
(8H, m), 4.36-4.82 (2H, m), 8.18 (1H, d, J = 2.0 Hz), 8.55
(1H, s).
Example 4
/0 3-((S)-2-amino-2-{cis-4-[4-(3-chloro-5-trifluoromethy1-2-
pyridy1)-1-piperaziny1]-1-cyclohexyl}acety1)-1,3-thiazolidine.
[0163]
a 0
N./NS
L_J
F3c
¨N H704
[0164]
The title compound (25 mg, yield 12%) was obtained as a
white powder using the cis form (249 mg) of Example 3 (1) and
in the same manner as in Example 1 (4).
1H-NMR (DMSO-d0 8 0.97-1.30 (4H, m), 1.40-1.92 (5H, m), 2.17-
2.28 (1H, m), 2.69 (4H, s), 3.01 (1H, t, J = 6.4 Hz), 3.07-
3.13 (1H, m), 3.20-3.95 (8H, m), 4.37-4.77 (2H, m), 5.06 (brs,
2H), 8.18 (1H, d, J = 2.0Hz), 8.54 (1H, s).
Example 5
3-[(S)-2-amino-2-(trans-4-{4-[4-(4-cyanopheny1)-2-thiazoly1]-
1-piperaziny1}-1-cyclohexyl)acety1]-1,3-thiazolidine
[0166]
0
N S
I N
[0167]
(1) Using the product (342 mg) resulting from Example 1 (2)
and 1-[4-(4-cyanopheny1)-2-thiazolyl]piperazine (270 mg) and
in the same manner as in Example 1 (3), 3-[(S)-2-tert-
butoxycarbonylamino-2-(4-{4-[4-(4-cyanopheny1)-2-thiazoly1]-1-
44
CA 02548918 2006-06-09
piperaziny11-1-cyclohexyl)acety1]-1,3-thiazolidine was
obtained as a yellow amorphous trans form (378 mg, yield
63.4%) and a yellow amorphous cis form (195 mg, yield 32.7%).
[0168]
(2) The title compound (175 mg, yield 55.2%) was obtained as a
pale-yellow powder using the above-mentioned trans form (372
mg) and in the same manner as in Example 1 (4).
1H-NMR (DMSO-d6) 8 1.25-1.85 (9H, m), 2.17-2.25 (1H, m), 2.52-
2.61 (4H, s), 3.00 (1H, t, J = 6.4 Hz), 3.04-3.15 (1H, m),
lo 3.25-4.05 (8H, m), 4.18-4.83 (3H, m), 7.59 (1H, s), 7.85 (2H,
d, J = 8.4 Hz), 8.04 (2H, d, J = 8.4 Hz).
Example 6
3-[(S)-2-amino-2-(cis-4-(4-[4-(4-cyanopheny1)-2-thiazoly1]-1-
piperaziny1}-1-cyclohexyl)acety1]-1,3-thiazolidine
[0170]
NC 0
0
N S
N
N L_I
S"¨"H ?N¨H2
[0171]
The title compound (43 mg, yield 27%) was obtained as a
pale-yellow powder using the cis form (195 mg) of Example 5
(1) and in the same manner as in Example 1 (4).
1H-NMR (DMSO-d0 8 0.97-1.30 (4H, m), 1.40-1.88 (5H, m), 2.18-
2.32 (1H, m), 2.55-2.65 (4H, m), 3.01 (1H, t, J = 6.4 Hz),
3.06-3.12 (1H, m), 3.25-3.95 (8H, m), 4.30-4.75 (4H, m), 7.58
(1H, s), 7.85 (2H, d, J = 8.4Hz), 8.04 (2H, d, J = 8.4 Hz).
Example 7
3-((S)-2-amino-2-{trans-4-[4-(3-methyl-1-pheny1-5-pyrazoly1)-
1-piperaziny1]-1-cyclohexyllacety1)-1,3-thiazolidine
trihydrochloride
[0173]
0
N.-44\ 7K __ \/, t-N\ P
jj¨NN
H _________________ NH2 3Ha
[0174]
CA 02548918 2006-06-09
(1) Using the product (514 mg) resulting from Example 1 (2)
and 1-(3-methyl-1-phenyl-5-pyrazolyl)piperazine (400 mg) and
in the same manner as in Example 1 (3), 3-((S)-2-tert-
butoxycarbonylamino-2-{4-[4-(3-methyl-1-pheny1-5-pyrazoly1)-1-
piperaziny1]-1-cyclohexyllacety1)-1,3-thiazolidine was
obtained as a white amorphous trans form (313 mg) and a white
amorphous cis form (398 mg).
[0175]
(2) 3-((S)-2-Amino-2-{trans-4-[4-(3-methy1-1-pheny1-5-
pyrazoly1)-1-piperaziny1]-1-cyclohexyl}acety1)-1,3-
thiazolidine (173 mg, yield 68.6%) was obtained as a white
amorphous form using the above-mentioned trans form (306 mg)
and in the same manner as in Example 1 (4).
[0176]
(3) The above-mentioned compound (232 mg) was dissolved in
ethyl acetate (4 mL), 4 mol/L hydrochloric acid-ethyl acetate
(0.40 mL) was added under ice-cooling, and the mixture was
stirred for 2 hr. The precipitate was collected by filtration
and washed with ethyl acetate to give the title compound (246
mg, yield 85.2%) as a white powder.
1H-NMR (DMSO-d6) 8 1.42-1.58 (2H, m), 1.68-2.10 (7H, m), 2.17
(3H, s), 2.97-4.27 (14H, s), 4.39-4.92 (2H, m), 5.92 (1H, s),
7.32 (1H, t, J = 7.5 Hz), 7.48 (2H, t, J = 7.5 Hz), 7.77 (1H,
d, J = 7.5 Hz), 8.41 (1H, brs), 10.63 (1H, brs).
Example 8
3-((S)-2-amino-2-{cis-4-[4-(3-methy1-1-pheny1-5-pyrazoly1)-1-
piperaziny1]-1-cyclohexyl}acety1)-1,3-thiazolidine
[0178]
0
N/NS
N N
N N
[0179]
The title compound (60 mg, yield 19%) was obtained as a
white powder using a mixture (390 mg) of a trans form and a
cis form of Example 7 (1) and in the same manner as in Example
46
CA 02548918 2006-06-09
1 (4).
1H-NMR (CDC13) 8 1.00-1.33 (4H, m), 1.40-1.75 (2H, m), 1.86-
2.00 (3H, m), 2.15-2.30 (3H, m), 2.54-2.63 (4H, m), 2.83-2.92
(4H, m), 3.01 (1H, t, J = 6.2 Hz), 3.09 (1H, t, J = 6.2 Hz),
3.28-3.37 (1H, m), 3.66-3.98 (2H, m), 4.45-4.71 (2H, m), 5.66
(1H, s), 7.23 (1H, t, J = 8.0 Hz), 7.40 (1H, t, J = 8.0 Hz),
7.76 (1H, d, J = 8.0 Hz).
Example 9
3-((S)-2-amino-2-{trans-4-[4-(3-bromo-1-isoquinoly1)-1-
piperaziny1]-1-cyclohexyl}acety1)-1,3-thiazolidine
trihydrochloride
[0181]
410
70___--N\ 7
_
Br \ -
____________________ 1-1 NH2 3HCI
[0182]
(1) Using the product (514 mg) resulting from Example 1 (2)
and 1-(3-bromo-1-isoquinolyl)piperazine (482 mg) and in the
same manner as in Example 1 (3), 3-[(S)-2-{4-[4-(3-bromo-1-
isoquinoly1)-1-piperaziny1]-1-cyclohexyl)-2-(tert-
butoxycarbonylamino)acety1]-1,3-thiazolidine was obtained as a
white amorphous trans form (426 mg) and a white amorphous cis
form (375 mg).
[0183]
(2) 3-((5)-2-Amino-2-{trans-4-[4-(3-bromo-l-isoquinoly1)-1-
piperaziny1]-1-cyclohexyl}acety1)-1,3-thiazolidine (293 mg,
yield 84.0%) was obtained as a white amorphous form using the
above-mentioned trans form (419 mg) and in the same manner as
in Example 1 (4).
[0184]
(3) The title compound (312 mg, yield 86.9%) was obtained as a
white powder using the above-mentioned compound (293 mg) and
in the same manner as in Example 7 (3).
1H-NMR (DMSO-d0 8 1.45-2.20 (9H, m), 3.06 (1H, t, J = 6.3 Hz),
3.13 (1H, t, J = 6.2 Hz), 3.27-4.33 (12H, m), 4.42-4.94 (2H,
47
CA 02548918 2006-06-09
m), 7.76 (1H, d, J = 7.8 Hz), 7.93 (1H, d, J = 7.8 Hz), 8.08
(1H, d, J = 7.8 Hz), 8.19 (1H, d, J = 7.8 Hz), 8.38 (1H, s),
8.48 (3H, brs), 10.90 (1H, brs).
Example 10
3-((S)-2-amino-2-{cis-4-[4-(3-bromo-l-isoquinoly1)-1-
piperaziny1]-1-cyclohexyl}acety1)-1,3-thiazolidine
[0186]
410 0
Br Ir\N-70d-NLI
_
N H NI-12
[0187]
The title compound (70 mg, yield 23%) was obtained as a
white powder using a mixture (368 mg) of the trans form and
the cis form of Example 9 (1) and in the same manner as in
Example 1 (4).
1H-NMR (DMSO-d0 8 0.90-1.42 (4H, m), 1.52-1.62 (1H, m), 1.73-
1.98 (4H, m), 2.18-2.32 (1H, m), 2.69-2.79 (4H, m), 2.99 (1H,
t, J = 6.4 Hz), 3.08 (1H, t, J = 6.3 Hz), 3.26-3.92 (7H, m),
4.36-4.71 (2H, m), 7.71 (1H, d, J = 8.0 Hz), 7.85 (1H, d, J =
8.0 Hz), 8.02 (1H, d, J = 8.0 Hz), 8.12 (1H, d, J = 8.0 Hz),
8.32 (1H, s).
Example 11
3-((5)-2-amino-2-{trans-4-[4-(2-trifluoromethyl-4-quinoly1)-1-
piperaziny1]-1-cyclohexyllacety1)-1,3-thiazolidine
dihydrochloride
[0189]
410 0
N -/ NN_704-1CP
H ___________________________ î-NH2 2HCI
F3C
[0190]
(1) Using the product (514 mg) resulting from Example 1 (2)
and 1-(2-trifluoromethy1-4-quinolyl)piperazine (464 mg) and in
the same manner as in Example 1 (3), 3-((S)-2-tert-
was
48
CA 02548918 2006-06-09
obtained as a pale-yellow amorphous trans form (578 mg, yield
63.4%), and a colorless cis oil (127 mg, yield 13.9%).
[0191]
(2) 3-((S)-2-Amino-2-{trans-4-[4-(2-trifluoromethy1-4-
quinoly1)-1-piperaziny1]-1-cyclohexyl}acety1)-1,3-thiazolidine
(325 mg, yield 68.0%) was obtained as a yellow oil using the
above-mentioned trans form (572 mg) and in the same manner as
in Example 1 (4).
[0192]
(3) The title compound (381 mg, yield 96.6%) was obtained as a
white powder using the above-mentioned compound (325 mg) and
in the same manner as in Example 7 (3).
1H-NMR (DMSO-d6) 8 1.45-1.63 (2H, m), 1.75-2.22 (7H, m), 3.06
(1H, t, J = 6.3 Hz), 3.14 (1H, t, J = 6.1 Hz), 3.31-3.53 (3H,
m), 3.60-4.95 (11H, m), 7.37 (1H, s), 7.48 (1H, t, J = 7.2
Hz), 7.89 (1H, t, J = 7.2 Hz), 8.05-8.18 (2H, m), 8.50 (3H,
brs).
Example 12
3-((S)-2-amino-2-{cis-4-[4-(2-trifluoromethy1-4-quinoly1)-1-
piperaziny1]-1-cyclohexyllacety1)-1,3-thiazolidine
dihydrochloride
[0194]
NS
N \
N H NH2 2HCI
F3C
[0195]
(1) 3-((S)-2-Amino-2-{cis-4-[4-(2-trifluoromethy1-4-quinoly1)-
1-piperaziny1]-1-cyclohexyl}acety1)-1,3-thiazolidine (81 mg,
yield 76%) was obtained as a colorless oil using the cis form
(127 mg) of Example 11 (1) and in the same manner as in
Example 1 (4).
[0196]
(2) The title compound (82 mg, yield 83%) was obtained as a
white powder using the above-mentioned compound (81 mg) and in
the same manner as in Example 7 (3).
49
CA 02548918 2006-06-09
1H-NMR (DMSO-d0 8 1.13-1.98 (7H, m), 2.23-2.38 (2H, m), 3.02-
3.29 (3H, m), 3.38-4.23 (11H, m), 4.39-4.87 (2H, m), 7.36 (1H,
s), 7.74 (1H, t, J = 7.8 Hz), 7.89 (1H, t, J = 7.8 Hz), 8.13
(1H, d, J = 7.8 Hz), 8.17 (1H, d, J = 7.8 Hz), 8.42 (3H, brs).
Example 13
3-((S)-2-amino-2-{trans-4-[4-(2-benzothiazoly1)-1-
piperaziny1]-1-cyclohexyl}acety1)-1,3-thiazolidine
[0198]
0
SZN
I N
--"-zz..-^S H NH2
[0199]
(1) Using the product (514 mg) resulting from Example 1 (2)
and 1-(2-benzothiazolyl)piperazine (362 mg) and in the same
manner as in Example 1 (3), 3-[(S)-2-14-[4-(2-benzothiazoly1)-
1-piperaziny1]-1-cyclohexyl)-2-(tert-
butoxycarbonylamino)acety1]-1,3-thiazolidine as a trans form
(488 mg, yield 59.6%), and a white cis solid (279 mg, yield
34.1 %).
[0200]
(2) The title compound (247 mg, yield 62.9%) was obtained as a
white powder using the above-mentioned trans form (481 mg) and
in the same manner as in Example 1 (4).
1H-NMR (DMSO-d0 8 1.20-1.83 (9H, m), 2.20 (1H, brs), 2.52-2.67
(4H, m), 2.98 (1H, t, J = 6.4 Hz), 3.09 (1H, t, J = 6.4 Hz),
3.24-4.00 (9H, m), 4.36-4.82 (2H, m), 7.07 (1H, t, J = 7.7
Hz), 7.27 (1H, t, J = 7.7 Hz), 7.45 (1H, d, J = 7.7 Hz), 7.76
(1H, d, J = 7.7 Hz).
Example 14
3-((5)-2-amino-2-{cis-4-[4-(2-benzothiazoly1)-1-piperaziny1]-
1-cyclohexyl}acety1)-1,3-thiazolidine
[0202]
0
N/NS
s F70 i---T?N--H2
[0203]
The title compound (98 mg, yield 44%) was obtained as a
CA 02548918 2006-06-09
=
white powder using the cis form (273 mg) of Example 13 (1) and
in the same manner as in Example 1 (4).
1H-NMR (DMSO-d0 5 0.88-1.98 (9H, m), 2.17-2.33 (1H, m), 2.53-
2.68 (4H, m), 2.98 (1H, t, J = 6.5 Hz), 3.07 (1H, t, J = 6.2
Hz), 3.20-3.92 (9H, m), 4.35-4.71 (2H,m), 7.06 (1H, t, J = 8.0
Hz), 7.27 (1H, t, J = 8.0 Hz), 7.44 (1H, d, J = 8.0 Hz), 7.75
(1H, d, J = 8.0 Hz).
Example 15
3-((S)-2-amino-2-{4-[4-(2-benzimidazolyl)piperidino]-1-
/0 cyclohexyllacety1)-1,3-thiazolidine trihydrochloride
[0205]
N/NS
nr-Ns)
L_I
1-7a1)--CNI-1
2 3HCI
[0206]
(1) The product (688 mg) resulting from Example 1 (2), 1-(2-
benzimidazolyl)piperidine (445 mg) and acetic acid (0.12 mL)
were dissolved in methanol (12 mL), sodium cyanoborohydride
(140 mg) was added, and the mixture was stirred at room
temperature for 28 hr. The reaction mixture was concentrated,
and saturated aqueous sodium hydrogencarbonate solution was
added to the residue. The mixture was extracted with
chloroform and the extract was washed with saturated brine and
dried. The solvent was evaporated under reduced pressure and
the residue was purified by silica gel chromatography to give
3-[(S)-2-14-[4-(2-benzimidazolyl)piperidino]-1-cyclohexy1}-2-
(tert-butoxycarbonylamino)acety1]-1,3-thiazolidine (445 mg,
yield 42.0%) as a pale-yellow amorphous form.
[0207]
(2) The above-mentioned compound (404 mg) was dissolved in
ethanol (3 mL), 4 mol/L hydrochloric acid-1,4-dioxane (3 mL)
was added, and the mixture was stirred for 6 hr. The reaction
mixture was concentrated under reduced pressure and ethyl
acetate (10 mL) was added to the residue. The solid was
collected by filtration and washed with ethyl acetate to give
51
CA 02548918 2006-06-09
the title compound (322 mg, yield 78.3%) as a white powder.
1H-NMR (DMSO-d6) 8 1.15-2.13 (8H, m), 2.18-2.32 (1H, m), 3.0-
5.0 (17H, m), 7.49-7.59 (2H, m), 7.75-7.86 (2H, m), 8.40, 8.48
(3H, brs), 10.7, 11.1 (1H, brs).
Example 16
3-{(S)-2-amino-2-[trans-4-(4-pheny1-1-piperaziny1)-1-
cyclohexyl]acety1)-1,3-thiazolidine
[0209]
INI"NS
NR2L-/
/o [0210]
(1) Using the product (630 mg) resulting from Example 1 (2)
and 1-phenylpiperazine (381 mg) and in the same manner as in
Example 1 (3), 3-{(S)-2-tert-butoxycarbonylamino-3-[trans-4-
(4-pheny1-1-piperaziny1)-1-cyclohexyl]acety1)-1,3-thiazolidine
was obtained as a white amorphous trans form (495 mg), and a
mixture (409 mg) of the trans form and a cis form in a white
amorphous form.
[0211]
(2) The title compound (156 mg, yield 39.0%) was obtained as a
white needle crystal using the above-mentioned trans form (487
mg) and in the same manner as in Example 1 (4).
1H-NMR (CDC13) 8 1.35-1.97 (9H, m), 2.18-2.27 (1H, m), 2.58-
2.70 (4H, m), 3.01 (1H, t, J = 6.5 Hz), 3.10 (1H, t, J = 6.2
Hz), 3.16-3.26 (4H, m), 3.39-3.51 (1H, m), 3.72-3.98 (2H, m),
4.52-4.70 (2H, m), 6.85 (1H, t, J = 7.8 Hz), 6.93 (2H, d, J =
7.8 Hz), 7.26 (2H, t, J = 7.8 Hz).
Example 17
3-{(S)-2-amino-2-[cis-4-(4-pheny1-1-piperaziny1)-1-
cyclohexyl]acety1)-1,3-thiazolidine
[0213]
NrNS
tnNI-H204
[0214]
The title compound (25 mg, yield 9.5%) was obtained as a
52
CA 02548918 2006-06-09
white powder using a mixture (403 mg) of the trans form and
the cis form of Example 16 (1) and in the same manner as in
Example 1 (4).
1H-NMR (CDC13) 8 1.04-1.78 (6H, m), 1.92-2.10 (3H, m), 2.23-
2.37 (1H, m), 2.70-2.78 (4H, m), 3.01 (1H, t, J = 6.4 Hz),
3.10 (1H, t, J = 6.2 Hz), 3.17-3.26 (4H, m), 3.31-3.39 (1H,
m), 3.78-3.98 (2H, m), 4.47-4.71 (2H, m), 6.85 (1H, t, J =
7.8Hz), 6.93 (2H, d, J = 7.8 Hz), 7.26 (2H, t, J = 7.8 Hz).
Example 18
3-1(S)-2-amino-3-[trans-4-(4-pheny1-1-piperaziny1)-1-
cyclohexyl]propiony1}-1,3-thiazolidine
[0216]
410
LN
H2N
0
[0217]
(1) 3-[(S)-2-tert-Butoxycarbonylamino-3-(4-hydroxy-1-
cyclohexyl)propiony1]-1,3-thiazolidine (44.6 g, yield 88.9%)
was obtained as a white amorphous form using L-tyrosine (25.4
g) and in the same manner as in Example 1 (1).
[0218]
(2) 3-[(S)-2-tert-Butoxycarbonylamino-3-(4-oxo-1-
cyclohexyl)propiony1]-1,3-thiazolidine (30.0 g, yield 71.9%)
was obtained as a colorless highly viscose oil using the
above-mentioned compound (42.0 g) and in the same manner as in
Example 1 (2).
1H-NMR (CDC13) 8 1.43 (9H, s), 1.32-1.70 (4H, m), 1.82-2.08
(2H, m), 2.28-2.45 (5H, m), 3.02 (1H, t, J = 6.3 Hz), 3.08-
3.17 (1H, m), 4.43-4.73 (3H, m), 5.29 (1H, d, J = 8.9 Hz).
[0219]
(3) Using the above-mentioned compound (740 mg) and 1-
phenylpiperazine (0.35 mL) and in the same manner as in
Example 1 (3), 3-[(S)-2-tert-butoxycarbonylamino-3-(4-oxo-1-
53
CA 02548918 2006-06-09
cyclohexyl)propiony1]-1,3-thiazolidine was obtained as a white
amorphous trans form (496 mg) and a mixture (379 mg) of the
trans form and a cis form in a white amorphous form.
[0220]
(4) The title compound (216 mg, yield 54.4%) was obtained as a
pale-yellow powder using the above-mentioned trans form (487
mg) and in the same manner as in Example 1 (4).
1H-NMR (CDC13) 8 1.32-1.44 (1H, m), 1.48-1.92 (10H, m), 2.21-
2.29 (1H, m), 2.64-2.73 (4H, m), 3.01 (1H, t, J = 6.3 Hz),
3.11 (1H, t, J = 6.1 Hz), 3.15-3.26 (4H, m), 3.52-3.96 (3H,
m), 4.43-4.68 (2H, m), 6.85 (1H, t, J = 7.5 Hz), 6.93 (2H, d,J
= 7.5Hz), 7.26 (2H, t, J = 7.5 Hz).
Example 19
3-{(S)-2-amino-3-[cis-4-(4-pheny1-1-piperaziny1)-1-
cyclohexyl]propiony11-1,3-thiazolidine trihydrochloride
[0222]
411 f-\141-11101W-1)
H2N
0 3Ha
[0223]
(1) 3-{(S)-2-Amino-3-[cis-4-(4-pheny1-1-piperaziny1)-1-
cyclohexyl]propiony11-1,3-thiazolidine (252 mg, yield 86.0%)
was obtained as a yellow oil using a mixture (379 mg) of the
trans form and the cis form of Example 18 (3) and in the same
manner as in Example 1 (4).
[0224]
(2) The title compound (166 mg, yield 83.7%) was obtained as a
white powder using the above-mentioned compound (150 mg) and
in the same manner as in Example 7 (3).
1H-NMR (DMSO-d6) 5 0.88-1.14 (1H, m), 1.43-2.28 (10H, m), 3.02-
4.08 (13H, m), 4.20-4.94 (3H, m), 6.87 (1H, t, J = 7.5Hz),
7.00 (2H, d, J = 7.5Hz), 7.27 (2H, t, J= 7.5 Hz), 8.33 (3H,
brs), 11.0 (1H, brs).
Example 20
3-((S)-2-amino-3-{trans-4-[4-(5-cyano-2-pyridy1)-1-
54
= CA 02548918 2006-06-09
piperaziny1]-1-cyclohexyl}propiony1)-1,3-thiazolidine
[0226]
NC¨Ã¨[N
H2N
0
[0227]
(1) Using the product (798 mg) resulting from Example 18 (2)
and 1-(5-cyano-2-pyridyl)piperazine (463 mg) and in the same
manner as in Example 1 (3), 3-((S)-2-tert-butoxycarbonylamino-
3-{trans-4-[4-(5-cyano-2-pyridy1)-1-piperaziny1]-1-
cyclohexyl}propiony1)-1,3-thiazolidine was obtained as a white,
amorphous trans form (607 mg, yield 51.3%) and a brown cis oil
(393 mg, yield 33.2%).
[0228]
(2) The title compound (201 mg, yield 41.3%) was obtained as a
white powder using the above-mentioned trans form (598 mg) and
in the same manner as in Example 1 (4).
1H-NMR (CDC13) 5 1.32-1.92 (11H, m), 2.20-2.29 (1H, m), 2.53-
2.66 (4H, m), 3.01 (IH, t, J = 6.3 Hz), 3.12 (1H, t, J = 6.2
Hz), 3.51-3.96 (7H, m), 4.43-4.68 (2H, m), 6.59 (1H, d, J =
9.1 Hz), 7.60 (1H, dd, J = 2.3, 9.1 Hz), 8.40 (1H, d, J = 2.3
Hz)
Example 21
3-((S)-2-amino-3-{cis-4-[4-(5-cyano-2-pyridy1)-1-piperaziny1]-
1-cyclohexyl}propiony1)-1,3-thiazolidine
[0230]
NC
LN
11:9)sjs13
H2N
0
[0231]
The title compound (42 mg, yield 13%) was obtained as a
white powder using the cis form (393 mg) of Example 20 (1) and
in the same manner as in Example 1 (4).
CA 02548918 2006-06-09
1H-NMR (CDC13) 8 0.87-1.12 (2H, m), 1.23-2.04 (9H,m), 2.26-2.35
(1H, m), 2.63-2.69 (4H, m), 3.01 (1H, t, J = 6.4 Hz), 3.10
(1H, t, J = 6.1 Hz), 3.53-3.94 (7H, m), 4.38-4.67 (2H, m),
6.58 (1H, d, J = 9.1 Hz), 7.59 (1H, dd, J = 2.4, 9.1 Hz), 8.40
(1H, d, J = 2.4 Hz).
Example 22
3-((S)-2-amino-3-{trans-4-[4-(3-methyl-1-pheny1-5-pyrazoly1)-
1-piperaziny1]-1-cyclohexyl}propiony1)-1,3-thiazolidine
trihydrochloride
/0 [0233]
H2NM---N
0 3HCI
[0234]
(1) Using the product (702 mg) resulting from Example 18 (2)
and 1-(3-methyl-1-pheny1-5-pyrazolyl)piperazine (525 mg) and
in the same manner as in Example 1 (3), 3-((S)-2-tert-
butoxycarbonylamino-3-{4-[4-(3-methyl-1-pheny1-5-pyrazoly1)-1-
piperaziny1]-1-cyclohexyl}propiony1)-1,3-thiazolidine was
obtained as a white amorphous trans form (477 mg) and a
mixture (431 mg) of the trans form and a cis form in a white
amorphous form.
[0235]
(2) 3-((S)-2-Amino-3-{trans-4-[4-(3-methy1-1-pheny1-5-
pyrazoly1)-1-piperaziny1]-1-cyclohexyl}propiony1)-1,3-
thiazolidine (286 mg, yield 73.5%) was obtained as a yellow
oil using the above-mentioned trans form (470 mg) and in the
same manner as in Example 1 (4).
[0236]
(3) The title compound (257 mg, yield 71.0%) was obtained as a
white powder using the above-mentioned compound (286 mg) and
in the same manner as in Example 7 (3).
1H-NMR (DMSO-d0 8 1.38-1.97 (11H, m), 2.17 (3H, s), 2.95-3.32
56
CA 02548918 2006-06-09
(9H, m), 3.42-3.53 (2H, m), 3.68-3.98 (2H, m), 4.13-4.90 (3H,
m), 5.91 (1H, s), 7.31 (1H, t, J = 7.5 Hz), 7.47 (2H, t, J =
7.5 Hz), 7.79 (2H, d, J = 7.5 Hz), 8.34 (3H, brs), 11.2(1H,
brs).
Example 23
3-((S)-2-amino-3-{cis-4-[4-(3-methyl-l-pheny1-5-pyrazoly1)-1-
piperaziny1]-1-cyclohexyl}propiony1)-1,3-thiazolidine
trihydrochloride
[0238]
14,
H (:)
H2NN
0 3HCI
[0239]
(1) 3-((S)-2-Amino-3-{cis-4-[4-(3-methy1-1-pheny1-5-
pyrazoly1)-1-piperaziny1]-1-cyclohexyllpropiony1)-1,3-
thiazolidine (135 mg, yield 38.2%) was obtained as a colorless
oil using a mixture (427 mg) of the trans form and the cis
form of Example 22 (1) and in the same manner as in Example 1
(4).
[0240]
(2) The title compound (122 mg, yield 72.1%) was obtained as a
white powder using the above-mentioned compound (135 mg) and
in the same manner as in Example 7 (3).
1H-N4R (DMSO-d0 5 0.85-1.10 (2H, m), 1.38-2.24 (13H, m), 2.97-
3.28 (9H, m), 3.42-4.03 (3H, m), 4.15-4.88 (3H, m), 5.91 (1H,
s), 7.31 (1H, t, J = 7.8 Hz), 7.48 (2H, t, J = 7.8 Hz), 7.77
(2H, d, J = 7.8 Hz), 8.35 (3H, brs), 11.3 (1H, brs).
Example 24
3-{(S)-2-amino-3-[trans-4-(4-nitrobenzylamino)-1-
cyclohexyl]propiony1}-1,3-thiazolidine dihydrochloride
[0242]
57
CA 02548918 2006-06-09
. = 27103-500
o2N,a,- H
H2N N
0 2HCI
[0243]
(1) The product (535 mg) resulting from Example 18 (2),
triethylamine (0.28 mL) and 4-nitrobenzylamine hydrochloride
(311 mg) were dissolved in chloroform (7 mL), sodium
triacetoxyborohydride (636 mg) was added, and the mixture was
stirred at room temperature for 5 hr. Saturated aqueous sodium
hydrogencarbonate solution was added to the reaction mixture,
and the mixture was extracted with chloroform. The extract was
1 washed with saturated brine and dried. The solvent was
evaporated under reduced pressure and the residue was purified
by silica gel chromatography to give 3-{(S)-2-tert-
butoxycarbonylamino-3-[4-(4-nitrobenzylamino)-1-
cyclohexyl]propiony11-1,3-thiazolidine was obtained as a white
amorphous trans form (412 mg) and a mixture (345 mg) of the
trans form and a cis form in a white amorphous form.
[0244]
(2) 3-{(S)-2-Amino-3-[trans-4-(4-nitrobenzy1amino)-1-
cyclohexyl]propiony1)-1,3-thiazolidine (312 mg, yield 96.0%)
was obtained as a yellow oil using the above-mentioned trans
form (408 mg) and in the same manner as in Example 1 (4).
[0245]
(3) The title compound (314 mg, yield 81.7%) was obtained as a
white powder using the above-mentioned compound (312 mg) and
in the same manner as in Example 7 (3).
1H-NMR (CDC13) 5 1.42-1.93 (11H, m), 3.02-4.05 (6H, m), 4.12-
4.93 (4H, m), 7.94 (2H, d, J = 8.6 Hz), 8.28 (2H, d, J = 8.6
Hz), 8.40 (brs, 2H).
Example 25
3-{(S)-2-amino-3-[cis-4-(4-nitrobenzylamino)-1-
cyclohexyl]propionyll-1,3-thiazolidine dihydrochloride
[0247]
58
= CA 02548918 2006-06-09
02N
H
H2 N Thr N
0 2HCI
[0248]
(1) 3-{(S)-2-Amino-3-[cis-4-(4-nitrobenzylamino)-1-
cyclohexyl]propiony1}-1,3-thiazolidine (115 mg, yield 42.7%)
was obtained as a colorless oil using a mixture (338 mg) of
the trans form and the cis form of Example 24 (1) and in the
same manner as in Example 1 (4).
[0249]
(2) The title compound (132 mg, yield 93.2%) was obtained as a
white powder using the above-mentioned compound (115 mg) and
in the same manner as in Example 7 (3).
1H-NMR (DMSO-d6) 8 0.82-1.08 (2H, m), 1.37-1.72 (6H, m), 1.90-
2.19 (3H, m), 2.77-3.96 (5H, m), 4.15-4.83 (5H, m), 7.89 (2H,
d, J = 8.6 Hz), 8.28 (2H, d, J = 8.6 Hz), 8.55 (brs, 2H).
Example 26
3-[(S)-2-amino-3-(4-anilino-1-cyclohexyl)propiony1]-1,3-
thiazolidine dihydrochloride
[0251]
N
ir
H2N N
0 2HCI
[0252]
(1) 3-[(S)-3-(4-Anilino-1-cyclohexyl)-2-tert-
(butoxycarbonylamino)propionyll-1,3-thiazolidine (584 mg,
yield 67.3%) was obtained as a white amorphous form using the
product (713 mg) resulting from Example 18 (2) and aniline
(0.20 mL) and in the same manner as in Example 1 (3).
[0253]
(2) 3-[(S)-2-Amino-3-(4-anilino-1-cyclohexyl)propiony1]-1,3-
thiazolidine (391 mg, yield 93.8%) was obtained as a colorless
59
CA 02548918 2006-06-09
27103-500
oil using the above-mentioned compound (542 mg) and in the
same manner as in Example 1 (4).
[0254]
(3) The title compound (427 mg, yield 88.6%) was obtained as a
white powder using the above-mentioned compound (391 mg) and
in the same manner as in Example 7 (3).
1H-NMR (DMSO-d0 8 0.88-1.11 (1H, m), 1.34-2.00 (10H, m), 2.98-
4.08 (4H, m), 4.15-4.93 (4H, m), 7.00-7.48 (511, m), 8.30 (brs,
3H).
/o [0255]
The compound of the present invention showed a potent .
DPP-IV inhibitory activity in Experimental Example 1 shown
below.
Experimental Example 1
(plasma DPP-IV inhibitory activity)
The plasma DPP-IV inhibitory activity of human and rat
was measured by the fluorescence assay method. Using Gly-Pro-
MCA (Peptide Institute Inc.) as a DPP-IV specific fluorescent
substrate, reaction solutions having the following
compositions and containing test substances having various
concentrations were incubated at room temperature for 60 min
and the measured (SPECTRA FLUOR, TECAN) fluorescent intensity
(Excitation 360 nm/Emission 465 nm) was taken as the DPP-IV
activity.
[0257]
As a buffer, 0.003% Brij-35-containing phosphate buffer
(PBS, Sigma-Aldrich Co.) was used.
A reaction solution free of the test substance was used
as a control.
[Table 1]
CA 02548918 2012-03-22
27103-500
Rat or human plasma (10-fold diluted solution) 20 AL/well
fluorescent substrate (100 Amol/L) 20 AL/well
test substance 20 AL/well
buffer 140 AL/well
total amount 200 AL/well
[0258]
The inhibitory rate of the test substance relative to the
reaction of the control was calculated, and IC50 values were
determined by logistic analysis. The IC50 values of the plasma
DPP-IV inhibitory activity of the present invention as
determined by the above method are shown in the following
table.
[Table 2]
Human plasma DPP-IV Rat plasma DPP-IV
Example compound
inhibitory activity inhibitory activity
No.
ICso 011.0 IC50 (nM)
2 1.6 1.4
14 2.1 1.4
Industrial Applicability
From the foregoing Experimental Examples, the a-amino
acid derivative of the present invention exhibits a potent
DPP-IV inhibitory activity and is useful for the prophylaxis
and/or treatment of diabetes, or the prophylaxis and/or
treatment of obesity.
61
